

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 April 2003 (24.04.2003)


PCT

(10) International Publication Number
WO 03/033657 A2

- (51) International Patent Classification⁷: **C12N**
- (21) International Application Number: **PCT/US02/32868**
- (22) International Filing Date: 16 October 2002 (16.10.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/329,815 16 October 2001 (16.10.2001) US
- (71) Applicant: **AVI BIOPHARMA, INC.** [US/US]; Suite 200, 4575 S.W. Research Way, Corvallis, OR 97333 (US).
- (72) Inventors: **STEIN, David, A.**; 1610 N.W. 23rd Street, Corvallis, OR 97330 (US). **SKILLING, Douglas, E.**; 2634 N.W. Acey Place, Corvallis, OR 97330 (US). **IVERSEN, Patrick, L.**; 5902 N.W. Fair Oaks Place, Corvallis, OR 97330 (US). **SMITH, Alvin, W.**; 26833 Sulphur Springs Road, Corvallis, OR 97330 (US).
- (74) Agents: **GORTHEY, LeeAnn** et al.; Perkins Coie LLP, P.O. Box 2168, Menlo Park, CA 94026 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: ANTISENSE ANTIVIRAL AGENT AND METHOD FOR TREATING SSRNA VIRAL INFECTION



(57) Abstract: This invention provides antisense antiviral compounds and methods of their use in inhibition of growth of viruses of the picomavirus, calicivirus, togavirus and flavivirus families, as in treatment of a viral infection. The antisense antiviral compounds are substantially uncharged oligomers having a targeting base sequence that is substantially complementary to a viral target sequence which spans the AUG start site of the first open reading frame of the viral genome.

WO 03/033657 A2

WO 03/033657 A2



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Antisense Antiviral Agent and Method for Treating ssRNA Viral Infection

5

Field of the Invention

This invention relates to antisense oligomers for use in treating a picornavirus, calicivirus, togavirus or flavivirus infection, antiviral treatment methods employing the oligomers, and methods for monitoring binding of antisense oligomers to a viral genome target site.

10

References

- Agrawal, S. *et al.*, *Proc. Natl. Acad. Sci. USA* **87**(4):1401-5 (1990).
- Alt, M. *et al.*, *Hepatology* **22**(3):707-17 (1995).
- 15 Alvarez-Salas, L. *et al.*, *Antisense Nucleic Acid Drug Dev.* **9**:441-450 (1999).
- Aurelian, L. *et al.*, *Antisense Nucleic Acid Drug Dev.* **10**:77-85 (2000).
- Bloomers, M., *Nuc Acids Res.* **22**(20):4187 (1994).
- Bonham, M.A. *et al.*, *Nucleic Acids Res.* **23**(7):1197-1203 (1995).
- Boudvillain, M. *et al.*, *Biochemistry* **36**(10):2925-31 (1997).
- 20 Clarke, G.E., and Lambden, P., *J. Infect. Dis.* **181**, S309-316 (2000).
- Cottral, G.E., in: *Manual of Standard Methods for Veterinary Microbiology*, Eds., Cornell University Press, Ithica, N.Y. pp.60-93.
- Cross, V. *et al.*, *Biochem* **36**:4096 (1997).
- Dagle *et al.*, *Nuc Acids Res.* **28**(10):2153 (2000).
- 25 Ding, D. *et al.*, *Nuc Acids Res.* **24**(2):354 (1996).
- Felgner *et al.*, *Proc. Nat. Acad. Sci. USA* **84**:7413 (1987).
- Gait, M.J.; *et al.*, *J. Chem. Soc. Perkin I*, 1684-1686 (1974).
- Gee, J.E. *et al.*, *Antisense & Nucleic Acid Drug Dev.* **8**:103-111 (1998).
- Green, K. *et al.*, *J. Am. Coll. Surg.* **191**:93-105 (2000).
- 30 Gutierrez, A. *et al.*, *Antiviral Research* **22**(1):1-13 (1993).

- Hanecak, R. *et al.*, *Journal of Virology* 70(8): 5203-12 (1996).
- Holland, J. in: *Emerging Virus*, Morse, S.S., Ed., Oxford University Press, New York and Oxford pp.203-218 (1993).
- Kusunoki, A. *et al.*, *Nucleosides Nucleotides Nucleic Acids* 19:1709-1719 (2000).
- 5 Lesnikowski, Z.J. *et al.*, *Nucleic Acids Research* 18(8):2109-15 (Apr 25, 1990).
- Matteucci, M. *Tetrahedron Lett.* 31:2385-2388 (1990).
- McElroy, E.B. *et al.*, *Bioorg. Med. Chem. Lett.* 4:1071 (1994).
- Mertes, M.P. *et al.*, *J. Med. Chem.* 12:154-157 (1969).
- Miller, P.S. *et al.*, in: *Antisense Research Applications*, Crooke, S.T. and Lebleu, B.,
 10 Eds., Boca Raton, CRC Press pp.189 (1993).
- Mizuta, T. *et al.*, *Nature Biotechnology* 17:583-587 (1999).
- Mohan, V. *et al.*, *Tetrahedron* 51:8655 (1995).
- Murray, R. *et al.*, in: *Medical Microbiology* (Third Edition) St. Louis Mo., Mosby Press
 pp.542-543 (1998).
- 15 O'Ryan, M. *et al.*, in: *Spector S, Lancz G, Eds., Clinical Virology Manual*, New York,
 Elsevier Science pp.361-196 (1992).
- Robbins, I. *et al.*, *Methods in Enzymology* 313:189-203 (1999).
- Roughton, A.L. *et al.*, *J. Am. Chem. Soc.* 117:7249 (1995).
- Smith, A. *et al.*, *Emerg. Inf. Dis.* 4:13-20 (1998a).
- 20 Smith A. *et al.*, *Clin. Inf. Dis.* 26:43-40 (1998b).
- Stein, C. *et al.*, *Pharmacol & Therapeutics*, 85:231 (2000).
- Toulme, J.J. *et al.*, *Biochimie* 78(7):663-73 (1996).
- Vasseur, J.J. *et al.*, *J. Am. Chem. Soc.* 114:4006 (1992).
- Wei, X. *et al.*, *Nucleic Acids Res.* 28:3065-3074 (2000).
- 25 Wu, G. *et al.*, *J. Biol. Chem.* 267:12436-12439 (1992).
- Xu, W., *Revue Scientifique et Technique*, Office of International des Epizooties 10:2393-
 2408 (1991).

Background of the Invention

- 30 RNA viruses cause many diseases in wildlife, domestic animals and humans. These
 viruses are genetically and antigenically diverse, exhibiting broad tissue tropisms and a

wide pathogenic potential. The incubation periods of some of the most pathogenic viruses, *e.g.* the caliciviruses, are very short. Viral replication and expression of virulence factors may overwhelm early defense mechanisms (Xu, 1991) and cause acute and severe symptoms.

- 5 There are no specific treatment regimes for many viral infections. The infection may be serotype specific and natural immunity is often brief or absent (Murray *et al.*, 1998). Immunization against these virulent viruses is impractical because of the diverse serotypes. RNA virus replicative processes lack effective genetic repair mechanisms, and current estimates of RNA virus replicative error rates are such that each genomic
- 10 replication can be expected to produce one to ten errors, thus generating a high number of variants (Hollan, 1993). Often, the serotypes show no cross protection, such that infection with any one serotype does not protect against infection with another. For example, vaccines against the vesivirus genus of the caliciviruses would have to provide protection against over 40 different neutralizing serotypes (Smith *et al.*, 1998a), and
- 15 vaccines for the other genera of the Caliciviridae are expected to have the same limitations.

Antisense agents have been proposed for treating various types of viral infection. In general, the specific proposals to date can be classified according to the type of virus targeted, the viral-genome target, and the type of oligonucleotide backbone employed in

20 the antisense compound. Among the viruses that have been targeted are vesicular stomatitis virus (Robbins and Lebleu, 1999), influenza virus (Mizuta *et al.*, 1999), hepatitis B virus (Wu and Wu, 1992), human papilloma virus (Alvarez-Salas *et al.*, 1999), herpes simplex virus (Aurelian and Smith, 2000), HIV (Kusunoki *et al.*, Wei *et al.*, 2000) and foot-and-mouth disease virus (Gutierrez *et al.*, 1993). Viral genome

25 targets that have been proposed include the IE-2 gene of cytomegalovirus (Green *et al.*, 2000), a stem-loop structure at the 5' non-coding region, the translation initiation codon, a core protein coding sequence of the hepatitis C virus, and the second functional initiator AUG of the foot-and-mouth disease virus (Hanecak *et al.*, 1996; Alt *et al.*, 1995; Gutierrez *et al.*, 1993). Finally, a wide variety of antisense backbone structures have

30 been proposed, including the negatively charged phosphorothioate (PSO) backbone oligomers, particularly the phosphorothioate oligodeoxynucleotides (Hanecak *et al.*, 1996; Alt *et al.*, 1995; Gutierrez *et al.*, 1993) and uniformly modified 2'-methoxyethoxy

phosphodiester oligonucleotide (Hanecak *et al.*, 1996).

Discovery and development generally involves demonstration of antiviral activity in cell culture. A compilation of antiviral experiments in cell culture is provided in Table 1 below.

5

TABLE 1. *In vitro* Antiviral Antisense Studies

Virus	Reference
Herpes Simplex	Gao <i>et al.</i> (1989) J. Biol. Chem. 264 : 11,521
Herpes Simplex	Hoke <i>et al.</i> (1991) Nucl. Acids Res. 19 : 5743
Herpes Simplex 1	Smith <i>et al.</i> (1986) Proc. Natl. Acad Sci 83 :2787
HIV-tat	Stevenson & Iversen (1989) J. Gen. Virol. 70 : 2673
HIV-aptamer	Matsukura <i>et al.</i> (1987) Proc. Natl. Acad Sci 84 :7706
HIV-rev	Matsukura <i>et al.</i> (1989) Proc. Natl. Acad Sci 86 :4244
HIV-gag	Agrawal <i>et al.</i> (1989) Proc. Natl. Acad Sci 86 :7790
HIV-LTR TAR element	Vickers <i>et al.</i> (1991) Nucl. Acids Res. 19 :3359
VSV	Agris <i>et al.</i> (1986) Biochemistry 25 :6268
VSV-N protein	Lamaitre <i>et al.</i> (1987) Proc. Natl. Acad Sci 84 :1987
HPV-E2	Cowsert <i>et al.</i> (1993) Antimic. Agent Chemo. 37 :
HBV surface gene	Goodarzi <i>et al.</i> (1990) J. Gen Virol. 71 :3021
HBV	Wu & Wu (1992) J Biol Chem 267 :12,436-12,439
SV40	Graessmann <i>et al.</i> (1991) Nucl. Acids Res. 19 :53
Influenza	Kabanov <i>et al.</i> (1990) FEBS Lett. 259 :327
Influenza	Leiter <i>et al.</i> (1990) Proc. Natl. Acad Sci 87 :3430
Rous Sarcoma Virus	Zamecnik & Stephenson (1978) Proc. Natl. Acad Sci 75 :280
CMV immed. early RNA	Anderson <i>et al.</i> (1996) Antimic. Agent Chemo. 40 :2004

Clinical trials have been initiated for antisense therapeutics targeting HIV, HPV, CMV and HCV (Table 2 below), all using phosphorothioate-linked oligonucleotides. As seen, the clinical trial experience to date indicates some failures, although antisense

10

TABLE 2. Clinical Trials with Antisense for Antiviral Therapy

Name	Company	Virus	Status
GEM91	Hybridon	HIV-gag	250 pts. Discont. 1997
ISIS2105	ISIS	HPV (6&11)	400 pts. Fail phase III
ISIS2922	ISIS	CMV-IE2	HIV retinitis approved
GEM132	Hybridon	CMV	Phase I
ISIS14803	ISIS	HCV	Phase I

The initial optimism towards antisense approaches to effective antiviral therapeutics has been blunted. Many of the effective antisense strategies employed in cell culture models (*e.g.* those in Table 1) have not successfully proceeded to clinical trials. The slow progress is due in part to the lack of robust cell culture models. For example, the HIV isolates that infect cultured cells do not generally reflect those found in the infected population, and the cell culture models do not integrate the roles of the multiple cell types infected. This problem is compounded by the lack of appropriate pre-clinical animal models for the full exploitation of viral gene expression and replication *in vivo*. Again, in the case of HIV, the human virus either does not infect animals, or, when primates are infected, they do not develop pathology similar to that seen in humans. The risk in developing antisense antiviral agents without robust culture models and appropriate animal models is great.


Thus, there remains a need for an effective antiviral therapy in several virus families, including small, single-stranded, positive-sense RNA viruses in the picornavirus, calicivirus, togavirus and flavivirus families. To meet this need, an antisense agent must be substantially stable against nuclease degradation, able to be taken up readily by virus-infected host cells following compound administration, and targeted against an effective region of the viral genome, that is, able to shut down viral replication.

Summary of the Invention

In one aspect, the invention provides an antiviral compound directed against an RNA virus from the picornavirus, calicivirus, togavirus or flavivirus families having a single-stranded, positive sense genome of less than 12 kb and a first open reading frame that encodes a polyprotein containing multiple functional proteins. The antiviral compound comprises a substantially uncharged oligomer having (a) a sequence of 12 to 40 subunits, supporting a targeting base sequence that is substantially complementary to a

viral target sequence which spans the translation initiation region of said first open reading frame, and (b) a substantially uncharged backbone.

In a preferred embodiment, the oligomer is a morpholino oligomer, having a sequence or morpholino subunits. The subunits are generally connected by uncharged, phosphorus-containing intersubunit linkages, which joining the morpholino nitrogen of one subunit to the 5' exocyclic carbon of an adjacent subunit. In one embodiment, these linkages are phosphorodiamidate linkages. For example, one embodiment of a morpholino subunit and phosphorodiamidate linkage may be represented by the structure:



10

where $Y_1=O$, $Z=O$, P_j is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide (where base-pairing moieties on different subunits may be the same or different), and X is alkyl, alkoxy, thioalkoxy, or alkyl amino. In one embodiment, $X=NR_2$, where each R is independently hydrogen or methyl. In an oligomer of such structural units, the phosphorus atom of one is bonded to the morpholino nitrogen of the next.

15

The substantially uncharged oligomer will typically have a T_m , with respect to binding to the viral target sequence, of greater than about 50 °C, as well as an ability to be actively taken up by mammalian cells. In addition, the compound can generally be recovered, in a heteroduplex form consisting of the oligomer and a complementary portion of the viral genome of the RNA virus, from the serum or urine of a mammalian subject, several hours after being administered to the subject.

20

In various embodiments, the antiviral compounds are directed against specific viruses or families. For example, selected embodiments include antiviral compounds directed against a picornavirus. Exemplary compounds include those having a targeting sequence having at least 90% homology to a sequence selected from the group consisting

25

of:

- (i) SEQ ID NO. 16, for a polio virus of the Mahoney and Sabin strains,
- (ii) SEQ ID NO. 17, for a hepatitis A virus,
- (iii) SEQ ID NO. 18, for a rhinovirus 14,
- 5 (iv) SEQ ID NO. 19, for a rhinovirus 16,
- (v) SEQ ID NO. 20, for a rhinovirus 1B,
- (vi) SEQ ID NOs. 21 and 22, for an Aphthovirus, and
- (vii) SEQ ID NOs 23, 24 and 25, for a coxsackie virus.

Other embodiments include antiviral compounds directed against a calicivirus.

- 10 Exemplary compounds include those having a targeting sequence having at least 90% homology to a sequence selected from the group consisting of:

- (i) SEQ ID NOs. 27, 28, and 29, for a serotype Pan-1 vesivirus,
- (ii) SEQ ID NO. 30, for a porcine vesivirus,
- (iii) SEQ ID NO. 31, for a Norwalk virus, and
- 15 (iv) SEQ ID NO. 32, for a feline vesivirus.

- Other embodiments include antiviral compounds directed against a togavirus. For use in inhibition of hepatitis E virus, the compound comprises an oligomer having a targeting sequence having at least 90% homology to a sequence selected from the group consisting of SEQ ID NOs: 33 and 34. Still other embodiments include antiviral
- 20 compounds directed against a togavirus. For use in inhibition of a hepatitis C flavivirus, the compound comprises an oligomer having a targeting sequence with at least 90% homology to SEQ ID NO. 35.

- In more specific embodiments, the compounds have the exact targeting sequences shown, and/or comprise phosphorodiamidate-linked morpholino oligomers. For
- 25 example, compounds directed against the serotype Pan-1 vesivirus may comprise a phosphorodiamidate-linked morpholino oligomer (PMO) having a targeting sequence selected from the group consisting of SEQ ID NOs. 27, 28, and 29. A compound directed against the feline vesivirus may comprise a PMO having the targeting sequence SEQ ID NO. 31.

- 30 In a related aspect, the invention provides a method of inhibiting replication of an RNA virus from the picornavirus, calicivirus, togavirus or flavivirus families, having a single-stranded, positive sense genome of less than 12 kb, and a first open reading frame

that encodes a polyprotein containing multiple functional proteins. The method comprises exposing the virus, or, typically, a cell infected with the virus, to a substantially uncharged morpholino oligomer having (a) a sequence of 12 to 40 subunits, supporting a targeting base sequence that is substantially complementary to a viral target sequence which spans the translation initiation region of the first open reading frame, and
5 (b) a substantially uncharged backbone. In one embodiment of the method, the oligomer is administered to a mammalian subject infected with the virus. Preferred embodiments of the antisense compounds, with respect to properties and structure, are as described above.

10 In a further aspect, the invention provides a method of confirming the presence of an effective interaction between a picornavirus, calicivirus, togavirus or flavivirus infecting a mammalian subject, and a substantially uncharged antisense oligomer targeted against the infecting virus. The method comprises:

- (a) administering the oligomer to the subject,
- 15 (b) at a selected time after said administration, obtaining a sample of a body fluid from the subject; and
- (c) assaying the sample for the presence of a nuclease-resistant heteroduplex comprising the antisense oligomer and a complementary portion of the viral target sequence. As above, the oligomer has a sequence of 12 to 40 subunits, supporting a
20 targeting base sequence that is substantially complementary to a viral target sequence which spans the translation initiation region of the first open reading frame (ORF1) of the infecting virus. Preferably, the oligomer is a morpholino oligomer, and has uncharged, phosphorus-containing intersubunit linkages joining the morpholino nitrogen of one subunit to the 5' exocyclic carbon of an adjacent subunit. In one embodiment, the
25 linkages are phosphorodiamidate linkages.

This method can be used in determining the effectiveness of treating a picornavirus, calicivirus, togavirus or flavivirus infection by administering the oligomer, by carrying out the described steps of administering, obtaining a sample, and assaying for heteroduplex at periodic intervals throughout a treatment period.

30 In addition, the method can be used in determining the identity of an infecting picornavirus, calicivirus, togavirus or flavivirus. The family or genus of such a virus can be determined by:

- 5 (a) providing a plurality of antisense oligomers, each having a base sequence that is substantially complementary to a viral target sequence of a plurality of known viruses selected from picornaviruses, caliciviruses, togaviruses or flaviviruses, wherein each said viral target sequence is (i) common to a virus family or genus, and (ii) not found in humans;
- (b) administering at least one oligomer of the plurality to the subject,
- (c) at a selected time after said administering, obtaining a sample of a body fluid from the subject;
- 10 (d) assaying the sample for the presence of a nuclease-resistant heteroduplex comprising the antisense oligomer and a complementary portion of the viral target sequence, and
- (e) identifying the family or genus of the infecting virus, based on the presence or absence of a heteroduplex comprising an administered antisense oligomer and a complementary portion of said viral target base sequence.

15 For identification of a specific infecting picornavirus, calicivirus, togavirus or flavivirus, the following further steps can be carried out:

- (a) providing a second plurality of antisense oligomers, each having a base sequence that is substantially complementary to a viral target sequence of one of a plurality of known viruses from the family or genus identified in step (e) above, wherein each said
- 20 viral target sequence is (i) specific to one of said known viruses, and (ii) not found in humans;
- (b) administering at least one oligomer of the plurality to the subject,
- (c) at a selected time after said administering, obtaining a sample of a body fluid from the subject;
- 25 (d) assaying the sample for the presence of a nuclease-resistant heteroduplex comprising the antisense oligomer and a complementary portion of the viral target sequence, and
- (e) identifying the infecting virus, based on the presence or absence of a heteroduplex comprising an administered antisense oligomer and a complementary
- 30 portion of said viral target base sequence.

These and other objects and features of the invention will be more fully appreciated when the following detailed description of the invention is read in conjunction with the

accompanying figures.

Brief Description of the Drawing

5 Figs. 1A-1E show several preferred morpholino-type subunits having 5-atom (A), six-atom (B) and seven-atom (C-E) linking groups suitable for forming polymers;

Figs. 2A-E show the repeating subunit segment of exemplary morpholino oligonucleotides, designated A through E, constructed using subunits A-E, respectively, of Figure 1;

10 Figs. 3A-3D are schematic diagrams of genomes of exemplary viruses and viral target sites;

Figs. 4A-4H show examples of uncharged linkage types in oligonucleotide analogs;

Fig. 5 shows percent inhibition of human rhinovirus *in vitro* in the presence of an antisense oligomer of the invention, having three base mismatches with the viral sequence, as described in Example 1;

15 Fig. 6 shows dose response data for an antisense oligomer of the invention in treating HCV infection in mice, as described in Example 4; doses are given in mg/mouse/day.

Detailed Description of the Invention

I. Definitions

20 The terms below, as used herein, have the following meanings, unless indicated otherwise:

The term "open reading frame" or "ORF" refers to a nucleotide sequence that includes a single 5' initiation codon, encodes one or more individual proteins, and
25 terminates at a termination codon.

The terms "polynucleotide", "oligonucleotide", and "oligomer" are used interchangeably and refer to a polymeric molecule having a backbone which supports bases capable of hydrogen bonding to typical polynucleotides, where the polymer backbone presents the bases in a manner to permit such hydrogen bonding in a sequence
30 specific fashion between the polymeric molecule and a typical polynucleotide (*e.g.*, single-stranded RNA, double-stranded RNA, single-stranded DNA or double-stranded DNA). "Polynucleotides" include polymers with nucleotides which are an N- or C-

glycoside of a purine or pyrimidine base, and polymers containing non-standard nucleotide backbones, for example, backbones formed using phosphorodiamidate morpholino chemistry, polyamide linkages (*e.g.*, peptide nucleic acids or PNAs) and other synthetic sequence-specific nucleic acid molecules.

5 A first sequence is an "antisense sequence" with respect to a second sequence if a polynucleotide with a first sequence specifically binds to, or specifically hybridizes with, a polynucleotide which has a second sequence, under physiological conditions.

 The terms "antisense oligonucleotide" and "antisense oligomer" refer to a sequence of subunits bearing nucleotide base-pairing moieties, linked by a subunit-to-subunit
10 backbone, that is effective to hybridize to a target sequence of a viral, positive-sense ssRNA. Typically, such an oligomer is from 8 to about 40 nucleotide subunits long, more typically about 12 to 40 nucleotide subunits long, and preferably about 12 to 30, or 12 to 25, subunits in length. The oligomer may have exact sequence complementarity to the target sequence or near complementarity, as defined below. Such an antisense
15 oligomer may block or inhibit the translation of a polyprotein encoded by the target open reading frame (ORF).

 A "subunit" of an oligonucleotide or oligonucleotide analog refers to one nucleotide (or nucleotide analog) unit of the oligomer. The term may refer to the nucleotide unit with or without the attached intersubunit linkage, although, when referring to a "charged
20 subunit", the charge typically resides within the intersubunit linkage (*e.g.* a phosphate or phosphorothioate linkage).

 A "morpholino oligomer" is an oligonucleotide analog composed of morpholino subunit structures of the form shown in Figs. 1A-E, where (i) the structures are linked together by phosphorus-containing linkages, one to three atoms long, joining the
25 morpholino nitrogen of one subunit to the 5' exocyclic carbon of an adjacent subunit, and (ii) P_i and P_j are purine or pyrimidine base-pairing moieties effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide. The purine or pyrimidine base-pairing moiety is typically adenine, cytosine, guanine, uracil or thymine. The synthesis, structures, and binding characteristics of morpholino oligomers are detailed in U.S.
30 Patent Nos. 5,698,685, 5,217,866, 5,142,047, 5,034,506, 5,166,315, 5,521,063, and 5,506,337, all of which are incorporated herein by reference.

 The subunit and linkage shown in Figure 1B are used for six-atom repeating-unit

backbones, as shown in Figure 2B (where the six atoms include: a morpholino nitrogen, the connected phosphorus atom, the atom (usually oxygen) linking the phosphorus atom to the 5' exocyclic carbon, the 5' exocyclic carbon, and two carbon atoms of the next morpholino ring). In these structures, the atom Y₁ linking the 5' exocyclic morpholino carbon to the phosphorus group may be sulfur, nitrogen, carbon or, preferably, oxygen. The X moiety pendant from the phosphorus is any stable group which does not interfere with base-specific hydrogen bonding. Preferred X groups include fluoro, alkyl, alkoxy, thioalkoxy, and alkyl amino, including cyclic amines, all of which can be variously substituted, as long as base-specific bonding is not disrupted. Alkyl, alkoxy and thioalkoxy preferably include 1-6 carbon atoms. Alkyl amino preferably refers to lower alkyl (C₁ to C₆) substitution, and cyclic amines are preferably 5- to 7-membered nitrogen heterocycles optionally containing 1-2 additional heteroatoms selected from oxygen, nitrogen, and sulfur. Z is sulfur or oxygen, and is preferably oxygen.

A preferred morpholino oligomer is a phosphorodiamidate-linked morpholino oligomer, referred to herein as a PMO. Such oligomers are composed of morpholino subunit structures such as shown in Fig. 2B, where X=NH₂, NHR, or NR₂ (where R is lower alkyl, preferably methyl), Y=O, and Z=O, and P_i and P_j are purine or pyrimidine base-pairing moieties effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide. Such a structure is also shown in Fig. 4H. Also preferred are structures having an alternate phosphorodiamidate linkage, where, in Fig. 2B, X = lower alkoxy, such as methoxy or ethoxy, Y=NH or NR, where R is lower alkyl, and Z=O.

The term "substituted", particularly with respect to an alkyl, alkoxy, thioalkoxy, or alkylamino group, refers to replacement of a hydrogen atom on carbon with a heteroatom-containing substituent, such as, for example, halogen, hydroxy, alkoxy, thiol, alkylthio, amino, alkylamino, imino, oxo (keto), nitro, cyano, or various acids or esters such as carboxylic, sulfonic, or phosphonic. It may also refer to replacement of a hydrogen atom on a heteroatom (such as an amine hydrogen) with an alkyl, carbonyl or other carbon containing group.

Polynucleotides are described as "complementary" to one another when hybridization occurs in an antiparallel configuration between two single-stranded polynucleotides. A double-stranded polynucleotide can be "complementary" to another polynucleotide, if hybridization can occur between one of the strands of the first

polynucleotide and the second. Complementarity (the degree that one polynucleotide is complementary with another) is quantifiable in terms of the proportion (*i.e.*, the percentage) of bases in opposing strands that are expected to form hydrogen bonds with each other, according to generally accepted base-pairing rules. An antisense oligomer
5 may have "near" or "substantial" complementarity to the target sequence and still functional for the purpose of the present invention. Preferably, the antisense oligomers employed have at most one mismatch with the target sequence out of 10 nucleotides, and preferably at most one mismatch out of 20, when compared to the exemplary oligomers having SEQ ID NOs: 16-35 as designated herein. Alternatively, the antisense oligomers
10 employed have at least 90% sequence homology, and preferably at least 95% sequence homology, with the exemplary oligomers having SEQ ID NOs: 16-35 as designated herein.

An oligonucleotide or antisense oligomer "specifically hybridizes" to a target polynucleotide if the oligomer hybridizes to the target under physiological conditions,
15 with a T_m substantially greater than 37°C, preferably at least 50°C, and typically 60°C-80°C or higher. Such hybridization preferably corresponds to stringent hybridization conditions. At a given ionic strength and pH, the T_m is the temperature at which 50% of a target sequence hybridizes to a complementary polynucleotide. Again, such hybridization may occur with "near" or "substantial" complementarity of the antisense
20 oligomer to the target sequence, as well as with exact complementarity.

A "nuclease-resistant" oligomeric molecule (oligomer) refers to one whose backbone is substantially resistant to nuclease cleavage, in non-hybridized or hybridized form; by common extracellular and intracellular nucleases in the body; that is, the oligomer shows little or no nuclease cleavage under normal nuclease conditions in the body to which the
25 oligomer is exposed.

A "heteroduplex" refers to a duplex between an antisense oligomer and the complimentary portion of a target RNA. A "nuclease-resistant heteroduplex" refers to a heteroduplex formed by the binding of an antisense oligomer to its complementary target, such that the heteroduplex is substantially resistant to *in vivo* degradation by intracellular
30 and extracellular nucleases, such as RNaseH, which are capable of cutting double-stranded RNA/RNA or RNA/DNA complexes.

As used herein, the term "target", relative to the viral genomic RNA or an mRNA,

refers to an mRNA or viral genomic RNA which is expressed or present in single-stranded in one or more types of mammalian cells.

5 A "base-specific intracellular binding event involving a target RNA" refers to the specific binding of an oligomer to a target RNA sequence inside a cell. The base specificity of such binding is sequence specific. For example, a single-stranded polynucleotide can specifically bind to a single-stranded polynucleotide that is complementary in sequence.

10 An "antisense oligomer composition" refers to a composition comprising one or more antisense oligomers for use in the RNA detection methods of the present invention. In some cases, such an "antisense oligomer composition" contains a plurality of antisense oligomers.

An "effective amount" of an antisense oligomer, targeted against an infecting ssRNA virus, is an amount effective to reduce the rate of replication of the infecting virus, and/or viral load, and/or symptoms associated with the viral infection.

15 As used herein, the term "body fluid" encompasses a variety of sample types obtained from a subject including, urine, saliva, plasma, blood, spinal fluid, or other sample of biological origin, such as skin cells or dermal debris, and may refer to cells or cell fragments suspended therein, or the liquid medium and its solutes.

20 The term "relative amount" is used where a comparison is made between a test measurement and a control measurement. The relative amount of a reagent forming a complex in a reaction is the amount reacting with a test specimen, compared with the amount reacting with a control specimen. The control specimen may be run separately in the same assay, or it may be part of the same sample (for example, normal tissue surrounding a malignant area in a tissue section).

25 "Treatment" of an individual or a cell is any type of intervention provided as a means to alter the natural course of the individual or cell. Treatment includes, but is not limited to, administration of *e.g.*, a pharmaceutical composition, and may be performed either prophylactically, or subsequent to the initiation of a pathologic event or contact with an etiologic agent. The related term "improved therapeutic outcome" relative to a patient
30 diagnosed as infected with a particular virus, refers to a slowing or diminution in the growth of virus, or viral load, or detectable symptoms associated with infection by that particular virus.

An agent is "actively taken up by mammalian cells" when the agent can enter the cell by a mechanism other than passive diffusion across the cell membrane. The agent may be transported, for example, by "active transport", referring to transport of agents across a mammalian cell membrane by *e.g.* an ATP-dependent transport mechanism, or by
5 "facilitated transport", referring to transport of antisense agents across the cell membrane by a transport mechanism that requires binding of the agent to a transport protein, which then facilitates passage of the bound agent across the membrane. For both active and facilitated transport, the antisense agent preferably has a substantially uncharged backbone, as defined below. Alternatively, the antisense compound may be formulated
10 in a complexed form, such as an agent having an anionic backbone complexed with cationic lipids or liposomes, which can be taken into cells by an endocytotic mechanism.

II. Targeted Viruses

The present invention is based on the discovery that effective inhibition of certain
15 classes of small, single-stranded, positive sense RNA viruses can be achieved by exposing cells infected with the virus to antisense compounds (i) targeted against the initiation region of the viral first open reading frame (ORF1) and (ii) having physical and pharmacokinetic features which allow effective interaction between the antisense compound and the virus within host cells. In one aspect, the oligomers can be used in
20 treating a mammalian subject infected with the virus.

The invention targets RNA viruses having genomes that are: (i) single stranded, (ii) positive polarity, (iii) less than 12 kb, and (iv) encoding a polyprotein at the first open reading frame (ORF1). In particular, targeted viral families include picornavirus, calicivirus, togavirus, and flavivirus. Various physical, morphological, and biological
25 characteristics of each of these four families, and members therein, can be found, for example, in *Textbook of Human Virology*, R. Belshe, ed., 2nd Edition, Mosby, 1991. Some of the key biological characteristics of each family are summarized below.

A. Picornavirus. The picornaviruses, which infect both humans and animals, can cause severe paralysis (paralytic poliomyelitis), aseptic meningitis, hepatitis,
30 pleurodynia, myocarditis, skin rashes, and colds; inapparent infection is common. Several medically important members include the poliovirus, hepatitis A virus, rhinovirus, Aphthovirus (foot-and mouth disease virus), and the coxsackie virus.

Rhinoviruses are recognized as the cause of the common cold in humans. Serotypes are designated from 1A to 100. Transmission is primarily by the aerosol route and the virus replicates in the nose.

Like all positive sense RNA viruses, the genomic RNA of Picornaviruses is
5 infectious; that is, the genomic RNA is able to direct the synthesis of viral proteins directly, without host transcription events.

B. Calicivirus. The caliciviruses infect both humans and animals. The genus vesivirus produces disease manifestations in mammals that include epithelial blistering and are suspected of being the cause of animal abortion storms and human hepatitis (non
10 A through E) (Smith *et al.*, 1998a and 1998 b). Other genera of the calicivirus include the Norwalk-like and Sapporo-like viruses, which together comprise the human calicivirus, and the lagoviruses, which cause hemorrhagic diseases in rabbits, a particularly rapid and deadly virus.

The human caliciviruses are the most common cause of viral diarrhea outbreaks
15 worldwide in adults, as well as being significant pathogens of infants (O'Ryan *et al.*, 1992). There are at least five types of human caliciviruses that inhabit the gastrointestinal tract. The Norwalk virus is a widespread human agent causing acute epidemic gastroenteritis and causes approximately 10% of all outbreaks of gastroenteritis in man (Murray *et al.*, 1998).

20 Vesiviruses are now emerging from being regarded as somewhat obscure and host specific to being recognized as one of the more versatile groups of viral pathogens known. For example, a single serotype has been shown to infect a diverse group of 16 different species of animals that include a saltwater fish (opal eye), sea lion, swine, and man.

25 C. Togavirus. Members of this family include the mosquito-borne viruses which infect both humans and animals. The family includes the genera Alphavirus, Rubivirus (rubella), Pestivirus (mucosal disease), Arterivirus (equine arteritis) and the Hepatitis E virus (HEV).

HEV was initially described in 1987 and first reported in the U.S. in 1991. The virus
30 was initially described as a Calicivirus based on the small, single-stranded RNA character. Some still classify HEV as a Calicivirus, but it has also been classified as a member of the Togavirus family. Infection appears to be much like hepatitis A viral

infection. The disease is an acute viral hepatitis which is apparent about 20 days after initial infection, and the virus may be observed for about 20 days in the serum.

Transmission occurs through contaminated water and geographically the virus is restricted to less developed countries.

- 5 D. Flavivirus. Members of this family include several serious human pathogens, among them mosquito-borne viruses of yellow fever, West Nile fever, hepatitis C, Japanese encephalitis, St. Louis encephalitis, Murray Valley encephalitis, and dengue.

 The flavivirus virion is approximately 40 to 50 nm in diameter. The symmetry of the flavivirus nucleocapsid has not been fully defined. It is known that the flavivirus
10 envelope contains only one species of glycoprotein. As yet, no subgenomic messenger RNA nor polyprotein precursors have been detected for the flavivirus.

III. Viral Target Regions

 The preferred target sequence is a region that spans the AUG start site of the first
15 open reading frame (ORF1) of the viral genome. The first ORF generally encodes a polypeptide containing non-structural proteins such as polymerases, helicases and proteases. By "spans the AUG start site" is meant that the target sequence includes at least three bases on one side of the AUG start site and at least two bases on the other (a total of at least 8 bases). Preferably, it includes at least four bases on each side of the
20 start site (a total of at least 11 bases).

 More generally, preferred target sites include targets that are conserved between a variety of viral isolates. Other favored sites include the IRES (internal ribosome entry site), transactivation protein binding sites, and sites of initiation of replication. Complex and large viral genomes, which may provide multiple redundant genes, may be efficiently
25 targeted by targeting host cellular genes coding for viral entry and host response to viral presence.

 A variety of viral-genome sequences are available from well known sources, such as the NCBI Genbank databases. Alternatively, a person skilled in the art can find sequences for many of the subject viruses in the open literature, *e.g.*, by searching for
30 references that disclose sequence information on designated viruses. Once a complete or partial viral sequence is obtained, the ORF1 of the virus is identified. Typically, the ORF1 is identified in the gene database or reference relied on. Alternatively, one may be

guided by the general genomic organization of the viruses, as described below for these four families. The AUG start site of ORF1 may also be identified in the gene database or reference relied upon, or it may be found by scanning the sequence for an AUG codon in the region of the expected ORF1 start site.

- 5 The general genomic organization of each of the four virus families is given below, followed by exemplary target sequences obtained for selected members (genera, species or strains) within each family.

A. Picornavirus. Fig. 3A shows the genome structure 10 of a picornavirus, in this case, a rhinovirus of the Picornavirus family. Typical of the picornavirus, the rhinovirus genome 10 is a single molecule of single-stranded, positive sense, polyadenylated RNA of approximately 7.5kb. As shown, the genome includes a long UTR 12, which is located upstream of the first polyprotein, and a single open reading frame (ORF) having a VPg (viral genome linked) protein covalently attached to its end. The ORF is subdivided into two segments (14, 16), each of which encodes a polyprotein. The first segment 14 encodes a polyprotein that is cleaved subsequently to form viral proteins VP1 to VP4, and the second segment 16 encodes a polyprotein which is the precursor of viral proteins including a Cis-pro, a protease, and a polymerase. The ORF terminates in a polyA termination sequence 18.

- The target initial AUG start site is located between base positions 615-640.
- 20 Targeting this region is effective to inhibit translation of both polyprotein segments 14, 16.

B. Calicivirus. Figure 3B shows the genome 20 of a calicivirus; in this case, a vesivirus of the Calicivirus family. The genome is a single molecule of infectious, single stranded, positive sense RNA of approximately 7.5kb. As shown, the genome 20 includes a UTR 22 upstream of the first open reading frame (ORF1) 24 which is unmodified. The 3' end 26 of genome 20 is polyadenylated. Genome 20 includes three open reading frames. The first open reading frame 24 encodes a polyprotein, which is subsequently cleaved to form the viral non-structural proteins including a helicase, a protease, an RNA dependent RNA polymerase, and "VPg", a protein that becomes bound to the 5' end of the viral genomic RNA (Clarke and Lambden, 2000). The second open reading frame 28 codes for the single capsid protein, and the third open reading frame 29 codes for what is reported to be a structural protein that is basic in nature and probably

able to associate with RNA (Green *et al.*, 2000).

The target initial AUG start site is located between base positions 7-35. Targeting this region is effective in inhibiting the translation of first reading frame 24.

C. Togavirus. Figure 3C shows the structure of the genome 30 of a togavirus; in this case, a rubella virus of the Togavirus family. Genome 30 is a single linear molecule of single-stranded, positive-sense RNA of approximately 11.7 kb, which is infectious. The 5' end 32 is capped with a 7-methylG molecule and the 3' end 34 is polyadenylated. Full-length and subgenomic messenger RNAs have been demonstrated, and post translational cleavage of polyproteins occurs during RNA replication. Genome 30 includes two open reading frames 36, 38. First open reading frame 36 encodes a polyprotein which is subsequently cleaved into four functional proteins, nsP1 to nsP4. Second open reading frame 38 encodes the viral capsid protein and three other viral proteins, PE2, 6K and E1. The AUG start site for first open reading frame 36 is located between base positions 10-40. Targeting this region is effective to inhibit the translation of first open reading frame 36.

D. Flavivirus. Figure 3D shows the structure of the genome 40 of the hepatitis C virus of the Flavivirus family. The hepatitis C virus genome is a single linear molecule of single-stranded, positive-sense RNA of about 11 kb. The 5' end 42 is capped with a m⁷GppAmp molecule, and the 3' end 44 is not polyadenylated. Genome 40 includes only one open reading frame 46 which encodes a precursor polyprotein separable into six structural and functional proteins. The initial AUG start site is located at base position 310.

GenBank references for exemplary viral nucleic acid sequences containing the ORF1 start site in the corresponding viral genomes are listed in Table 3, below. It will be appreciated that these sequences are only illustrative of other sequences in the ORF1 start-site region of members of the four virus families, as may be available from available gene-sequence databases of literature or patent resources. The sequences below, identified as SEQ ID NOs 1-15, are listed in Table 10 at the end of the specification.

Table 3. Exemplary Viral Nucleic Acid Sequences Spanning the AUG Site of ORF1

Virus	GenBank Acc. No.	Nucleotides (Target Seq.)	SEQ ID NO.
Picornaviridae			
Poliovirus Mahoney strain	NC 002058	735-754	1
Poliovirus Sabin strain	V01150	735-754	2
Hepatitis A	M14707	731-754	3
Rhinovirus 14	NC 001490	621-640	4
Rhinovirus 16	NC 001752	618-637	5
Rhinovirus 1B	D00239	615-634	6
Aphthovirus	NC 003082	711-732	7
	NC 002554	1033-1058	8
Coxsackievirus	M16560	735-754	9
Caliciviridae			
Vesivirus (Pan-1)	AF091736	1-34	10
Porcine	AF182760	6-25	11
Norwalk	AF093797	1-19	12
Togaviridae			
Hepatitis E	NC 001434	5-28	13
		1-18	14
Flaviviridae			
Hepatitis C	AF169005	348-330	15

As indicated above, the targeting sequence, that is, the base sequence of the antisense oligomer, is preferably directed against an AUG-spanning portion of the viral target sequence. In particular, the targeting sequence is complementary, or substantially complementary, as defined above, to a portion of the target region spanning the AUG start site of the first open reading frame of the viral genome, and the degree of complementarity between the target and targeting sequence is sufficient to form a stable duplex. At a minimum length of 8 bases, the targeting sequence includes a CAT sequence directed against the AUG codon, and at least three bases on one side of this sequence, and two on the other. The region of complementarity of the antisense oligomers with the target RNA sequence may be as short as 8-11 bases, but is preferably 12-15 bases or more, *e.g.* 12-20 bases, or 12-25 bases. An antisense oligomer of about

15 bases is generally long enough to have a unique complementary sequence in the viral genome. In addition, a minimum length of complementary bases may be required to achieve the requisite binding T_m , as discussed below.

Oligomers as long as 40 bases may be suitable, where at least the minimum number of bases, *e.g.*, 8-11, preferably 12-15 bases, are complementary to the target sequence. In general, however, facilitated or active uptake in cells is optimized at oligomer lengths less than about 30, preferably less than 25, and more preferably 20 or fewer bases. For PMO oligomers, described further below, an optimum balance of binding stability and uptake generally occurs at lengths of 13-18 bases.

The oligomer may be 100% complementary to the viral nucleic acid target sequence, or it may include mismatches, *e.g.*, to accommodate variants, as long as a heteroduplex formed between the oligomer and viral nucleic acid target sequence is sufficiently stable to withstand the action of cellular nucleases and other modes of degradation which may occur *in vivo*. Oligomer backbones which are less susceptible to cleavage by nucleases are discussed below. Mismatches, if present, are less destabilizing toward the end regions of the hybrid duplex than in the middle. The number of mismatches allowed will depend on the length of the oligomer, the percentage of G:C base pairs in the duplex, and the position of the mismatch(es) in the duplex, according to well understood principles of duplex stability. Although such an antisense oligomer is not necessarily 100% complementary to the viral nucleic acid target sequence, it is effective to stably and specifically bind to the target sequence, such that a biological activity of the nucleic acid target, *e.g.*, expression of viral protein(s), is modulated.

The stability of the duplex formed between the oligomer and the target sequence is a function of the binding T_m and the susceptibility of the duplex to cellular enzymatic cleavage. The T_m of an antisense compound with respect to complementary-sequence RNA may be measured by conventional methods, such as those described by Hames *et al.*, *Nucleic Acid Hybridization*, IRL Press, 1985, pp.107-108. Each antisense oligomer should have a binding T_m , with respect to a complementary-sequence RNA, of greater than body temperature and preferably greater than 50°C. T_m 's in the range 60-80°C or greater are preferred. According to well known principles, the T_m of an oligomer compound, with respect to a complementary-based RNA hybrid, can be increased by increasing the ratio of C:G paired bases in the duplex, and/or by increasing the length (in

base pairs) of the heteroduplex. At the same time, for purposes of optimizing cellular uptake, it may be advantageous to limit the size of the oligomer. For this reason, compounds that show high T_m (50°C or greater) at a length of 15 bases or less are generally preferred over those requiring 20+ bases for high T_m values.

5 Table 4 lists exemplary targeting sequences directed against a target region that spans the translation initiation site of the first open reading frame (ORF1) of selected viruses of the picornavirus, calicivirus, togavirus, and flavivirus families. These sequences were selected, as indicated above, by constructing a complementary sequence to one or more sequences spanning the AUG site in the target sequences given above.

10 Exceptions to this general rule are the following: SEQ ID NO: 26 is directed to the origin of the viral genome; SEQ ID NOs: 23-25 contain mismatches and/or inserts, as indicated by underlining; and SEQ ID NO: 33 includes only one base of the ATG start codon.

Table 4.

Exemplary Antisense Sequences Targeting the ORF1 Translation Initiation Region

Virus	GenBank Acc. No.	Targeted Region	Antisense Oligomer (5' to 3')	Seq. ID No.
Picornaviridae				
Poliovirus Mahoney strain Sabin strain	NC002058 V01150	735-755 735-755	CCTGAGCACCCATTATGATAC	16
Hepatitis A	M14707	731-754	CCTTGTCTAGACATGTTTCATTATT	17
Rhinovirus 14	NC001490	621-640	CTGAGCGCCCATGATCACAG	18
Rhinovirus 16	NC001752	618-637	TTGAGCGCCCATGATAACAA	19
Rhinovirus 1B	D00239	615-634	CTGGGCACCCATGATGCCAA	20
Aphthovirus	NC003082	711-732	AAACAGTCAGTTGTGCTCATTG	21
	NC002554	1037-1058	AAACAGTCAGTTGTATTCATAG	22
Coxsackievirus	M16560	735-754	CTTGAGCTCCCATT ¹ TTGCTG	23
			CTTGAGCCCCCAT ¹ TTTGTGTTG	24
			CCTGTGCTCCCAT ¹ CTTGATG	25
		1-30	TGGGTGGGATCAACCCACAGGCTG TTTTAA	26
Caliciviridae				
Vesivirus (Pan-1)	AF091736	7-26	GAGCCATAGCTCAAATTCTC	27
		1-21	TAGCTCAAATTCTCATTTAC	28
		15-34	GAGCGTTTGAGCCATAGCTC	29
Porcine	AF182760	6-25	GACGGCAATTAGCCATCACG	30
Norwalk	AF093797	1-19	CGACGCCATCATCATTCAC	31
Feline	AF479590	14-34	CAGAGTTTGAGACATTGTCTC	32
Togaviridae				
Hepatitis E	NC001434	6-28	CCTTAATAAACTGATGGGCCTCC	33
		1-18	CTGATGGGCCTCCATGGC	34
Flaviviridae				
Hepatitis C	AF169005	348-330	GTGCTCATGGTGCACGGTC-3	35

IV. Antisense Oligomers

5

A. Properties

As detailed above, the oligomer has a base sequence directed against a targeted

portion of the viral genome, preferably spanning the ORF1 start site. In addition, the oligomer is able to effectively target infecting viruses, when administered to an infected host cell, *e.g.* in an infected mammalian subject.

The latter requirement is met when the oligomer compound (a) has the ability to be
5 actively taken up by mammalian cells, and (b) once taken up, form a duplex with the target ssRNA with a T_m of greater than about 50 °C.

As will be described below, the ability to be taken up by cells requires that the oligomer backbone be substantially uncharged, and, preferably, that the oligomer structure is recognized as a substrate for active or facilitated transport across the cell
10 membrane. The ability of the oligomer to form a stable duplex with the target RNA will also depend on the oligomer backbone, as well as factors noted above, the length and degree of complementarity of the antisense with respect to the target, the ratio of G:C to A:T base matches, and the positions of any mismatched bases. The ability of the antisense agent to resist cellular nucleases promotes survival and ultimate delivery of the
15 agent to the cell cytoplasm.

Below are disclosed methods for testing any given, substantially uncharged backbone for its ability to meet these requirements.

A1. Active or facilitated uptake by cells

The antisense compound may be taken up by host cells by facilitated or active
20 transport across the host cell membrane if administered in free (non-complexed) form, or by an endocytotic mechanism if administered in complexed form.

In the case where the agent is administered in free form, the antisense compound should be substantially uncharged, meaning that a majority of its intersubunit linkages are uncharged at physiological pH. Experiments carried out in support of the invention
25 indicate that a small number of net charges, *e.g.*, 1-2 for a 15- to 20-mer oligomer, can in fact enhance cellular uptake of certain oligomers with substantially uncharged backbones. The charges may be carried on the oligomer itself, *e.g.*, in the backbone linkages, or may be terminal charged-group appendages. Preferably, the number of charged linkages is no more than one charged linkage per four uncharged linkages. More
30 preferably, the number is no more than one charged linkage per ten, or no more than one per twenty, uncharged linkages. In one embodiment, the oligomer is fully uncharged.

An oligomer may also contain both negatively and positively charged backbone

linkages, as long as opposing charges are present in approximately equal number.

Preferably, the oligomer does not include runs of more than 3-5 consecutive subunits of either charge. For example, the oligomer may have a given number of anionic linkages, *e.g.* phosphorothioate or N3'→P5' phosphoramidate linkages, and a comparable number of cationic linkages, such as N,N-diethylenediamine phosphoramidates (Dagle, 2000).
The net charge is preferably neutral or at most 1-2 net charges per oligomer.

In addition to being substantially or fully uncharged, the antisense agent is preferably a substrate for a membrane transporter system (*i.e.* a membrane protein or proteins) capable of facilitating transport or actively transporting the oligomer across the cell membrane. This feature may be determined by one of a number of tests for oligomer interaction or cell uptake, as follows.

A first test assesses binding at cell surface receptors, by examining the ability of an oligomer compound to displace or be displaced by a selected charged oligomer, *e.g.*, a phosphorothioate oligomer, on a cell surface. The cells are incubated with a given quantity of test oligomer, which is typically fluorescently labeled, at a final oligomer concentration of between about 10-300 nM. Shortly thereafter, *e.g.*, 10-30 minutes (before significant internalization of the test oligomer can occur), the displacing compound is added, in incrementally increasing concentrations. If the test compound is able to bind to a cell surface receptor, the displacing compound will be observed to displace the test compound. If the displacing compound is shown to produce 50% displacement at a concentration of 10X the test compound concentration or less, the test compound is considered to bind at the same recognition site for the cell transport system as the displacing compound.

A second test measures cell transport, by examining the ability of the test compound to transport a labeled reporter, *e.g.*, a fluorescence reporter, into cells. The cells are incubated in the presence of labeled test compound, added at a final concentration between about 10-300 nM. After incubation for 30-120 minutes, the cells are examined, *e.g.*, by microscopy, for intracellular label. The presence of significant intracellular label is evidence that the test compound is transported by facilitated or active transport.

The antisense compound may also be administered in complexed form, where the complexing agent is typically a polymer, *e.g.*, a cationic lipid, polypeptide, or non-biological cationic polymer, having an opposite charge to any net charge on the antisense

compound. Methods of forming complexes, including bilayer complexes, between anionic oligonucleotides and cationic lipid or other polymer components, are well known. For example, the liposomal composition Lipofectin® (Felgner *et al.*, 1987), containing the cationic lipid DOTMA (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride) and the neutral phospholipid DOPE (dioleoyl phosphatidyl ethanolamine), is widely used. After administration, the complex is taken up by cells through an endocytotic mechanism, typically involving particle encapsulation in endosomal bodies.

Alternatively, and according to another aspect of the invention, the requisite properties of oligomers with any given backbone can be confirmed by a simple *in vivo* test, in which a labeled compound is administered to an animal, and a body fluid sample, taken from the animal several hours after the oligomer is administered, assayed for the presence of heteroduplex with target RNA. This method is detailed in subsection D below.

15 A2. Substantial resistance to RNaseH

Two general mechanisms have been proposed to account for inhibition of expression by antisense oligonucleotides. (See *e.g.*, Agrawal *et al.*, 1990; Bonham *et al.*, 1995; and Boudvillain *et al.*, 1997). In the first, a heteroduplex formed between the oligonucleotide and the viral RNA acts as a substrate for RNaseH, leading to cleavage of the viral RNA. Oligonucleotides belonging, or proposed to belong, to this class include phosphorothioates, phosphotriesters, and phosphodiester (unmodified "natural" oligonucleotides). However, because such compounds would expose the viral RNA in an oligomer:RNA duplex structure to proteolysis by RNaseH, and therefore loss of duplex, they are suboptimal for use in the present invention.

25 A second class of oligonucleotide analogs, termed "steric blockers" or, alternatively, "RNaseH inactive" or "RNaseH resistant", have not been observed to act as a substrate for RNaseH, and are believed to act by sterically blocking target RNA nucleocytoplasmic transport, splicing or translation. This class includes methylphosphonates (Toulme *et al.*, 1996), morpholino oligonucleotides, peptide nucleic acids (PNA's), certain 2'-O-allyl or 30 2'-O-alkyl modified oligonucleotides (Bonham, 1995), and N3'→P5' phosphoramidates (Gee, 1998; Ding, 1996).

A test oligomer can be assayed for its RNaseH resistance by forming an

RNA:oligomer duplex with the test compound, then incubating the duplex with RNaseH under a standard assay conditions, as described in Stein *et al.* After exposure to RNaseH, the presence or absence of intact duplex can be monitored by gel electrophoresis or mass spectrometry.

5 A3. In vivo uptake

In accordance with another aspect of the invention, there is provided a simple, rapid test for confirming that a given antisense oligomer type provides the required characteristics noted above, namely, high T_m , ability to be actively taken up by the host cells, and substantial resistance to RNaseH. This method is based on the discovery that a properly designed antisense compound will form a stable heteroduplex with the complementary portion of the viral RNA target when administered to a mammalian subject, and the heteroduplex subsequently appears in the urine (or other body fluid). Details of this method are also given in co-owned U.S. Patent applications, Serial No. 09/736,920, entitled "Non-Invasive Method for Detecting Target RNA" (Non-
10 Invasive Method), the disclosure of which is incorporated herein by reference.

Briefly, a test oligomer containing a backbone to be evaluated, having a base sequence targeted against a known RNA, is injected into a mammalian subject. The antisense oligomer may be directed against any intracellular RNA, including a host RNA or the RNA of an infecting virus. Several hours (typically 8-72) after administration, the urine is assayed for the presence of the antisense-RNA heteroduplex. If heteroduplex is detected, the backbone is suitable for use in the antisense oligomers of the present invention.

The test oligomer may be labeled, *e.g.* by a fluorescent or a radioactive tag, to facilitate subsequent analyses, if it is appropriate for the mammalian subject. The assay can be in any suitable solid-phase or fluid format. Generally, a solid-phase assay involves first binding the heteroduplex analyte to a solid-phase support, *e.g.*, particles or a polymer or test-strip substrate, and detecting the presence/amount of heteroduplex bound. In a fluid-phase assay, the analyte sample is typically pretreated to remove interfering sample components. If the oligomer is labeled, the presence of the heteroduplex is confirmed by detecting the label tags. For non-labeled compounds, the heteroduplex may be detected by immunoassay if in solid phase format or by mass spectroscopy or other known methods if in solution or suspension format.

When the antisense oligomer is complementary to a virus-specific region of the viral genome (such as the translation initiation region of ORF1, as described above), the method can be used to detect the presence of a given ssRNA virus, or reduction in the amount of virus during a treatment method.

5 B. Exemplary oligomer backbones

Examples of nonionic linkages that may be used in oligonucleotide analogs are shown in Figs. 4A-4H. In these figures, B represents a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, preferably selected from adenine, cytosine, guanine and uracil. Suitable backbone structures include carbonate (4A, R=O) and carbamate (4A, R=NH₂) linkages, (Mertes, 1969; Gait, 1974); alkyl phosphonate and phosphotriester linkages (4B, R=alkyl or -O-alkyl) (Miller, 1993; Lesnikowski, 1990); amide linkages (4C) (Bloomers, 1994); sulfone and sulfonamide linkages (4D, R₁, R₂ = CH₂) (Roughten, 1995; McElroy, 1994); and a thioformacetyl linkage (4E) (Matteucci, 1990; Cross, 1997). The latter is reported to have enhanced duplex and triplex stability with respect to phosphorothioate antisense compounds (Cross, 1997). Also reported are the 3'-methylene-N-methylhydroxyamino compounds of structure 4F (Mohan, 1995).

Peptide nucleic acids (PNAs) (Fig. 4G) are analogs of DNA in which the backbone is structurally homomorphous with a deoxyribose backbone, consisting of N-(2-aminoethyl) glycine units to which pyrimidine or purine bases are attached. PNAs containing natural pyrimidine and purine bases hybridize to complementary oligonucleotides obeying Watson-Crick base-pairing rules, and mimic DNA in terms of base pair recognition (Egholm *et al.*, 1993). The backbone of PNAs are formed by peptide bonds rather than phosphodiester bonds, making them well-suited for antisense applications. The backbone is uncharged, resulting in PNA/DNA or PNA/RNA duplexes which exhibit greater than normal thermal stability. PNAs are not recognized by nucleases or proteases.

A preferred oligomer structure employs morpholino-based subunits bearing base-pairing moieties, joined by uncharged linkages, as described above. Especially preferred is a substantially uncharged phosphorodiamidate-linked morpholino oligomer, such as illustrated in Fig. 4H and in Fig. 2B-B. Morpholino oligonucleotides, including antisense oligomers, are detailed, for example, in co-owned U.S. Patent Nos. 5,698,685, 5,217,866,

5,142,047, 5,034,506, 5,166,315, 5,185, 444, 5,521,063, and 5,506,337, all of which are expressly incorporated by reference herein.

Important properties of the morpholino-based subunits shown in Figs. 1A-E include: the ability to be linked in an oligomeric form by stable, uncharged backbone linkages; the ability to support a nucleotide base (*e.g.* adenine, cytosine, guanine or uracil) such that the polymer formed can hybridize with a complementary-base target nucleic acid, including target RNA, with high T_m , even with oligomers as short as 10-14 bases; the ability of the oligomer to be actively transported into mammalian cells; and the ability of the oligomer:RNA heteroduplex to resist RNase degradation.

Exemplary backbone structures for antisense oligonucleotides of the invention include the β -morpholino subunit types shown in Figs. 1A-E, each linked by an uncharged, phosphorus-containing subunit linkage. Fig. 1A shows a phosphorus-containing linkage which forms the five atom repeating-unit backbone shown Fig. 2A, where the morpholino rings are linked by a 1-atom phosphoamide linkage. Fig. 1B shows a linkage which produces a 6-atom repeating-unit backbone, as shown in Fig. 2B. In this structure, the atom Y linking the 5' morpholino carbon to the phosphorus group may be sulfur, nitrogen, carbon or, preferably, oxygen. The X moiety pendant from the phosphorus may be fluorine, an alkyl or substituted alkyl, an alkoxy or substituted alkoxy, a thioalkoxy or substituted thioalkoxy, or unsubstituted, monosubstituted, or disubstituted nitrogen, including cyclic structures, such as morpholines or piperidines. Alkyl, alkoxy and thioalkoxy preferably include 1-6 carbon atoms. The Z moieties are sulfur or oxygen, and are preferably oxygen. The linkage shown in Figs. 1C-E are designed for 7-atom unit-length backbones, as shown for structures in Figs. 2C-E. In Structure 2C, the X moiety is as in Structure 2B, and the moiety Y may be methylene, sulfur, or, preferably, oxygen. In Structure 2D, the X and Y moieties are as in Structure 2B. In structure 2E, X is as in Structure 2B, and Y is O, S, or NR, where R is hydrogen or lower alkyl, preferably hydrogen or methyl. In all subunits depicted in Figs. 2A-E, Z is O or S, and each of P_i and P_j is a base pairing moiety, preferably selected from adenine, cytosine, guanine and uracil.

Particularly preferred morpholino oligonucleotides include those composed of morpholino subunit structures of the form shown in Fig. 2B, where $X=NH_2$ or $N(CH_3)_2$, $Y=O$, and $Z=O$.

As noted above, the substantially uncharged oligomer may advantageously include a limited number of charged linkages, *e.g.* up to about 1 per every 5 uncharged linkages, more preferably up to about 1 per every 10 uncharged linkages. Therefore a small number of charged linkages, *e.g.* charged phosphoramidate or phosphorothioate, may also be incorporated into the oligomers. In the case of the morpholino oligomers, such a charged linkage may be a linkage as represented by any of Figs. 2A-E, where X is oxide ($-O^-$) or sulfide ($-S^-$).

The antisense compounds can be prepared by stepwise solid-phase synthesis, employing methods detailed in the references cited above. In some cases, it may be desirable to add additional chemical moieties to the antisense compound, *e.g.* to enhance pharmacokinetics or to facilitate capture or detection of the compound. Such a moiety may be covalently attached, typically to a terminus of the oligomer, according to standard synthetic methods. For example, addition of a polyethyleneglycol moiety or other hydrophilic polymer, *e.g.*, one having 10-100 monomeric subunits, may be useful in enhancing solubility. One or more charged groups, *e.g.*, anionic charged groups such as an organic acid, may enhance cell uptake. A reporter moiety, such as fluorescein or a radiolabeled group, may be attached for purposes of detection. Alternatively, the reporter label attached to the oligomer may be a ligand, such as an antigen or biotin, capable of binding a labeled antibody or streptavidin. In selecting a moiety for attachment or modification of an oligomer antisense, it is generally of course desirable to select chemical compounds of groups that are biocompatible and likely to be tolerated by a subject without undesirable side effects.

V. Inhibition of Viral Replication

The antisense compounds detailed above are useful in inhibiting replication of ssRNA viruses of the picornavirus, calicivirus, togavirus, and flavivirus families. In one embodiment, such inhibition is effective in treating infection of a host animal by these viruses. Accordingly, the method comprises, in one embodiment, contacting a cell infected with the virus with an antisense agent effective to inhibit the translation of a polypeptide encoded in the first open reading frame of the genome of the specific virus. In a further embodiment, the antisense agent is administered to a mammalian subject, *e.g.*, human or domestic animal, infected with a given virus, in a suitable pharmaceutical

carrier. It is contemplated that the antisense oligonucleotide arrests the growth of the RNA virus in the host. The RNA virus may be decreased in number or eliminated with little or no detrimental effect on the normal growth or development of the host.

A. Identification of the Infective Agent

5 The specific virus causing the infection can be determined by methods known in the art, *e.g.* serological or cultural methods, or by methods employing the antisense oligomers of the present invention.

 Serological identification employs a viral sample or culture isolated from a biological specimen, *e.g.*, stool, urine, cerebrospinal fluid, blood, etc., of the subject.
10 Immunoassay for the detection of virus is generally carried out by methods routinely employed by those of skill in the art, *e.g.*, ELISA or Western blot. In addition, monoclonal antibodies specific to particular viral strains or species are often commercially available.

 Culture methods may be used to isolate and identify particular types of virus, by
15 employing techniques including, but not limited to, comparing characteristics such as rates of growth and morphology under various culture conditions.

 Another method for identifying the viral infective agent in an infected subject employs one or more antisense oligomers targeting broad families and/or genera of viruses, *e.g.*, Picornaviridae, Caliciviridae, Togaviridae and Flaviviridae. Sequences
20 targeting any characteristic viral RNA can be used. The desired target sequences are preferably (i) common to broad virus families/genera, and (ii) not found in humans. Characteristic nucleic acid sequences for a large number of infectious viruses are available in public databases, and may serve as the basis for the design of specific oligomers.

25 For each plurality of oligomers, the following steps are carried out: (a) the oligomer(s) are administered to the subject; (b) at a selected time after said administering, a body fluid sample is obtained from the subject; and (c) the sample is assayed for the presence of a nuclease-resistant heteroduplex comprising the antisense oligomer and a complementary portion of the viral genome. Steps (a) – (c) are carried
30 for at least one such oligomer, or as many as is necessary to identify the virus or family of viruses. Oligomers can be administered and assayed sequentially or, more conveniently, concurrently. The virus is identified based on the presence (or absence) of

a heteroduplex comprising the antisense oligomer and a complementary portion of the viral genome of the given known virus or family of viruses.

Preferably, a first group of oligomers, targeting broad families, is utilized first, followed by selected oligomers complementary to specific genera and/or species and/or strains within the broad family/genus thereby identified. This second group of oligomers includes targeting sequences directed to specific genera and/or species and/or strains within a broad family/genus. Several different second oligomer collections, *i.e.* one for each broad virus family/genus tested in the first stage, are generally provided. Sequences are selected which are (i) specific for the individual genus/species/strains being tested and (ii) not found in humans.

B. Administration of the Antisense Oligomer

Effective delivery of the antisense oligomer to the target nucleic acid is an important aspect of treatment. In accordance with the invention, routes of antisense oligomer delivery include, but are not limited to, various systemic routes, including oral and parenteral routes, *e.g.*, intravenous, subcutaneous, intraperitoneal, and intramuscular, as well as inhalation, transdermal and topical delivery. The appropriate route may be determined by one of skill in the art, as appropriate to the condition of the subject under treatment. For example, an appropriate route for delivery of an antisense oligomer in the treatment of a viral infection of the skin is topical delivery, while delivery of an antisense oligomer for the treatment of a viral respiratory infection is by inhalation. The oligomer may also be delivered directly to the site of viral infection, or to the bloodstream.

The antisense oligomer may be administered in any convenient vehicle which is physiologically acceptable. Such a composition may include any of a variety of standard pharmaceutically accepted carriers employed by those of ordinary skill in the art. Examples include, but are not limited to, saline, phosphate buffered saline (PBS), water, aqueous ethanol, emulsions, such as oil/water emulsions or triglyceride emulsions, tablets and capsules. The choice of suitable physiologically acceptable carrier will vary dependent upon the chosen mode of administration.

In some instances, liposomes may be employed to facilitate uptake of the antisense oligonucleotide into cells. (See, *e.g.*, Williams, S.A., *Leukemia* 10(12):1980-1989, 1996; Lappalainen *et al.*, *Antiviral Res.* 23:119, 1994; Uhlmann *et al.*, ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE, *Chemical Reviews*, Volume 90, No.

4, pages 544-584, 1990; Gregoriadis, G., Chapter 14, *Liposomes, Drug Carriers in Biology and Medicine*, pp. 287-341, Academic Press, 1979). Hydrogels may also be used as vehicles for antisense oligomer administration, for example, as described in WO 93/01286. Alternatively, the oligonucleotides may be administered in microspheres or
5 microparticles. (See, *e.g.*, Wu, G.Y. and Wu, C.H., *J. Biol. Chem.* 262:4429-4432, 1987)

Sustained release compositions may also be used. These may include semipermeable polymeric matrices in the form of shaped articles such as films or microcapsules.

In one aspect of the method, the subject is a human subject, *e.g.*, a patient diagnosed
10 as having a localized or systemic viral infection. The condition of a patient may also dictate prophylactic administration of an antisense oligomer of the invention, *e.g.* in the case of a patient who (1) is immunocompromised; (2) is a burn victim; (3) has an indwelling catheter; or (4) is about to undergo or has recently undergone surgery. In one preferred embodiment, the oligomer is a phosphorodiamidate morpholino oligomer,
15 contained in a pharmaceutically acceptable carrier, and is delivered orally. In another preferred embodiment, the oligomer is a phosphorodiamidate morpholino oligomer, contained in a pharmaceutically acceptable carrier, and is delivered intravenously (IV).

In another application of the method, the subject is a livestock animal, *e.g.*, a chicken, turkey, pig, cow or goat, etc, and the treatment is either prophylactic or
20 therapeutic. The invention also includes a livestock and poultry food composition containing a food grain supplemented with a subtherapeutic amount of an antiviral antisense compound of the type described above. Also contemplated is, in a method of feeding livestock and poultry with a food grain supplemented with subtherapeutic levels of an antiviral, an improvement in which the food grain is supplemented with a subtherapeutic
25 amount of an antiviral oligonucleotide composition as described above.

The antisense compound is generally administered in an amount and manner effective to result in a peak blood concentration of at least 200-400 nM antisense oligomer. Typically, one or more doses of antisense oligomer are administered, generally at regular intervals, for a period of about one to two weeks. Preferred doses for oral
30 administration are from about 1-25 mg oligomer per 70 kg. In some cases, doses of greater than 25 mg oligomer/patient may be necessary. For IV administration, preferred doses are from about 0.5 mg to 10 mg oligomer per 70 kg. The antisense oligomer may

be administered at regular intervals for a short time period, *e.g.*, daily for two weeks or less. However, in some cases the oligomer is administered intermittently over a longer period of time. Administration may be followed by, or concurrent with, administration of an antibiotic or other therapeutic treatment. The treatment regimen may be adjusted (dose, frequency, route, etc.) as indicated, based on the results of immunoassays, other biochemical tests and physiological examination of the subject under treatment.

C. Monitoring of Treatment

An effective *in vivo* treatment regimen using the antisense oligonucleotides of the invention may vary according to the duration, dose, frequency and route of administration, as well as the condition of the subject under treatment (*i.e.*, prophylactic administration versus administration in response to localized or systemic infection).

Accordingly, such *in vivo* therapy will often require monitoring by tests appropriate to the particular type of viral infection under treatment, and corresponding adjustments in the dose or treatment regimen, in order to achieve an optimal therapeutic outcome.

Treatment may be monitored, *e.g.*, by general indicators of infection, such as complete blood count (CBC), nucleic acid detection methods, immunodiagnostic tests, viral culture, or detection of heteroduplex.

The efficacy of an *in vivo* administered antisense oligomer of the invention in inhibiting or eliminating the growth of one or more types of RNA virus may be determined from biological samples (tissue, blood, urine etc.) taken from a subject prior to, during and subsequent to administration of the antisense oligomer. Assays of such samples include (1) monitoring the presence or absence of heteroduplex formation with target and non-target sequences, using procedures known to those skilled in the art, *e.g.*, an electrophoretic gel mobility assay; (2) monitoring the amount of viral protein production, as determined by standard techniques such as ELISA or Western blotting, or (3) measuring the effect on viral titer, *e.g.* by the method of Spearman-Kärber. (See, for example, Pari, G.S. *et al.*, *Antimicrob. Agents and Chemotherapy* 39(5):1157-1161, 1995; Anderson, K.P. *et al.*, *Antimicrob. Agents and Chemotherapy* 40(9):2004-2011, 1996, Cottral, G.E. (ed) in: *Manual of Standard Methods for Veterinary Microbiology*, pp.60-93, 1978).

A preferred method of monitoring the efficacy of the antisense treatment is by detection of the antisense-RNA heteroduplex. At selected time(s) after antisense

administration, a body fluid is collected for detecting the presence and/or measuring the level of heteroduplex species in the sample. Typically, the body fluid sample is collected 3-24 hours after administration, preferably about 6-24 hours after administering. As indicated above, the body fluid sample may be urine, saliva, plasma, blood, spinal fluid, or other liquid sample of biological origin, and may include cells or cell fragments suspended therein, or the liquid medium and its solutes. The amount of sample collected is typically in the 0.1 to 10 ml range, preferably about 1 ml or less.

The sample may be treated to remove unwanted components and/or to treat the heteroduplex species in the sample to remove unwanted ssRNA overhang regions, *e.g.* by treatment with RNase. It is, of course, particularly important to remove overhang where heteroduplex detection relies on size separation, *e.g.*, electrophoresis of mass spectroscopy.

A variety of methods are available for removing unwanted components from the sample. For example, since the heteroduplex has a net negative charge, electrophoretic or ion exchange techniques can be used to separate the heteroduplex from neutral or positively charged material. The sample may also be contacted with a solid support having a surface-bound antibody or other agent specifically able to bind the heteroduplex. After washing the support to remove unbound material, the heteroduplex can be released in substantially purified form for further analysis, *e.g.*, by electrophoresis, mass spectroscopy or immunoassay.

EXAMPLES

The following examples illustrate but are not intended in any way to limit the invention.

Materials and Methods

Standard recombinant DNA techniques were employed in all constructions, as described in Ausubel, FM *et al.*, in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley and Sons, Inc., Media, PA, 1992 and Sambrook, J. *et al.*, in MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, Vol. 2, 1989).

Example 1: Antisense inhibition of Picornaviridae (Human rhinovirus) *in vitro*

The inhibitory effect on rhinovirus 16 of a phosphorodiamidate morpholino oligomer (PMO) having a sequence targeted to the translation initiation zone of rhinovirus 14 was evaluated. The phosphorodiamidate morpholino oligomers (PMO) were synthesized at AVI BioPharma (Corvallis, OR), as described in Summerton and Weller, 1997. Purity of the full-length oligomer was greater than 90% as determined by reverse-phase high-pressure liquid chromatography and MALDI TOF mass spectroscopy. The lyophilized PMOs were dissolved in sterile 0.9% NaCl and filtered through 0.2 µm Acrodisc filters (Gelman Sciences, Ann Arbor, MI) prior to use in cell cultures.

The PMO includes a nucleic acid sequence targeting rhinovirus 14 and containing three mispairs in respect to the rhinovirus 16 target sequence. The target sequence (GenBank NC001752 618-637; SEQ ID NO: 5) and targeting sequence (SEQ ID NO: 18) are as follows:

15	HRV-16:	TTGTTATCAT GGG CGCTCAA	SEQ ID NO: 5
	HRV-14 antisense:	<u>G</u> ACACTAGT A CCCGCGAGTC	SEQ ID NO: 18

where the bolded codon is the start codon, and the mispairs are underlined.

Twenty-four hour old cultures of HeLa cells were grown in six well plates for 24 hours. Confluent monolayers were propagated in Earles minimal essential medium (MEM) supplemented with 5% bovine calf serum, L-glutamine, antibiotics, and sodium bicarbonate. Cells were incubated at 37°C in a 5% CO₂ humidified atmosphere. Prior to treatment, the monolayers were rinsed twice with MEM without serum.

The PMOs were introduced into the cultured cells by a "scrape-loading" method, which is known to deliver PMOs to 80-90% of the adherent cells in the culture (Partridge *et al.*, 1996). The oligomers were diluted to a final concentration of 20µM in MEM without serum. A 0.5 ml volume of oligomer-MEM media was added to the cultures and after 1 minute at room temperature the cells were gently scraped off with a rubber policeman. The cells were returned to the CO₂ incubator for 10 minutes, then diluted into 8 ml of MEM with calf serum and dispersed in 0.1 ml per well of a 96-well plate containing log dilutions of rhinovirus 16 (8 wells per dilution). The plates were incubated for 72 hours at 37°C in the CO₂ incubator, after which time they were

examined with an Olympus CK light microscope for the presence of cytopathic effect. Viral titers (TCID₅₀) were determined by the method of Spearman-Kärber. Viral titer for the different treatment groups is shown in Table 6 below and graphically in Fig. 5.

5

Table 6

<u>Treatment</u>	<u>Viral Titer</u>
saline	4.0×10^7
HRV-14 AS	5.32×10^6

The results show greater than 75% inhibition of the viral titer of HRV-16 when treated with PMO antisense to the HRV-14. While efficacy is lower than the efficacy of rhinovirus 16 targeting sequence directed against rhinovirus 16 infection, demonstrated in a previous study, as expected from the three mismatched basepairs, the study confirms the antiviral effects of PMOs substantially complementary to the translation initiation zone of the HRV-16 genome.

Example 2: Antisense inhibition of Caliciviridae Vesivirus isolates PCV Pan-1 and SMSV-13 in Porcine kidney (PK-15) and African Green Monkey Kidney (Vero) tissue culture

The antiviral efficacy of three phosphorodiamidate morpholino oligomers (PMO) targeted to the ORF1 translation initiation zone of the strains Pan-1 and SMSV-13 of the vesivirus genus of *Caliciviridae* was evaluated. The PMOs were scrape-loaded, as described above, to two host cell lines, Porcine kidney cells (PK-15) (ATCC No. CCL33) and African Green Monkey Kidney cells (ATCC No. CCL81) (Vero), which were subsequently exposed to vesiviruses of the strains Pan-1 and SMSV-13. The protocol of Example 1 was followed for incubation and determination of viral load.

The three PMOs each included a targeting sequence complementary to the Pan-1 sequence (GenBank accession no. AF091736) spanning the start codon of ORF1. PMOs were used at a concentration of 20 μ M in serum free media. A saline blank and scrambled sequence control PMO were included in the study. The PMO sequences, identified as ORF1.1 (SEQ ID NO. 27), ORF1.2 (SEQ ID NO. 28), and ORF1.3 (SEQ ID NO. 29), and the target site locations are listed in Table 7 below.

30

Table 7. Oligomer Sequences and Target Locations

Oligomer	Target Location in Pan-1	Sequence, 3'	SEQ ID NO:
ORF1.1	7-26	GAG CCA TAG CTC AAA TTC TC	27
ORF1.2	1-21	TAG CTC AAA TTC TCA TTT AC	28
ORF1.3	15-34	GAG CGT TTG AGC CAT AGC TC	29
Scrambled control	-	GAC ATA TCT AAT CAT ATA C	36

The inhibitory effects of the PMOs on the viral titer of SMSV-13 and Pan-1 in both PK-15 and Vero cells are provided in Table 8. A simple percent inhibition average is presented when both cell types were tested with a given viral strain.

Table 8. Effects of antisense PMOs on viral titers of vesiviruses, strains PCV Pan-1 and SMSV-13, in PK-15 and Vero host cells.

PMO (20 μM)	VMK cells (TCID₅₀/ml)	PK-15 cells (TCID₅₀/ml)	% Inhib. (Avg)
Virus strain SMSV-13			
Saline	5.3 x 10 ⁷	7.1 x 10 ⁵	0
ORF1.1	1.7 x 10 ⁷	5.3 x 10 ⁴	80
ORF1.2	3.0 x 10 ⁷		43
ORF1.3	1.7 x 10 ⁷	3.0 x 10 ⁵	68
Scrambled control	7.1 x 10 ⁷	9.5 x 10 ⁵	-33
Virus strain Pan-1			
Saline	7.1 x 10 ⁶	2.2 x 10 ⁶	0
ORF1.1	1.3 x 10 ⁶	3.0 x 10 ⁵	84
ORF1.2	2.2 x 10 ⁶		68
ORF1.3	4.0 x 10 ⁶		44
Scrambled control		2.3 x 10 ⁶	-5

Significant inhibition of viral titer was observed with the ORF1-targeting PMOs in both cell lines and for both viral serotypes, with "ORF1.1" being most effective. The scrambled control PMO had no inhibitory effect.

In dose response studies, Vero cells were loaded with PMOs having ORF1.1 and

following the protocol described in Example 1. Treatment with the ORF1.1 PMO gave no inhibition at 0.2 and 1.0 μM , moderate inhibition at 2.0 μM , and high inhibition at 20 μM . The ORF1.3 PMO gave no inhibition of SMSV-13 viral titer at 0.2 μM , but inhibition was high at 1.0 μM ; no additional inhibition was observed at 2, 10, and 20 μM .

Example 3: Effect of PMO antisense to feline calicivirus.

A feline calicivirus that became a hemorrhagic virus to the cat was isolated and propagated in a cell culture. The cell culture was exposed, following the protocol described in Example 1, to an antisense PMO having the following targeting sequence: CAG AGT TTG AGA CAT TGT CTC (SEQ ID No. 32). A one-log reduction of viral titer was observed in the cell culture.

Example 4: Effect of an Antisense PMO Targeted to HCV Viremia in HCV-Trimera Mice

The study was performed on pathogen-free female CB6F1 and SCID/beige mice obtained from Harlan Inc. (reared and maintained in the Weizmann Institute Animal Breeding Center). The mice were housed in a specific pathogen-free environment; allowed sterile food and acidified water ad lib prior to initiation of the study.

CB6F1 mice were thymectomized at the age of 7-9 weeks. Experiments were performed using CB6F1 mice at the age of 12-18 weeks (19-25 g/mouse). Prior to heterotransplantation, the CB6F1 mice received a split dose of total body irradiation (4 Gy followed 1 day later by 11 Gy) from a gamma beam 150-A ^{60}Co source (Atomic Energy of Canada) with irradiation rate of 0.7 Gy/min. After the first irradiation, ciprofloxacin (20 $\mu\text{g/ml}$; Bayer) was added to drinking water for 7-10 days. Immediately after the second radiation dose, mice were injected i.v. with $4-6 \times 10^6$ bone-marrow cells (in 0.2 ml PBS) obtained from 6-10 weeks old SCID/beige mice.

CB6F1 mice were anesthetized with 10 mg/mouse of 2,2,2 tribromoethanol (Aldrich) and a laparotomy performed. Human liver fragments infected *ex vivo* with hepatitis C virus (HCV) were transplanted behind the ear pinna. The incisions were closed with 9 mm autoclip wound clips.

closed with 9 mm autoclip wound clips.

The mice were treated with PMO antisense to the HCV nucleic sequence spanning the AUG site of the first open reading frame, having the targeting sequence GTG CTC ATG GTG CAG GGT C (SEQ ID No. 35). Treatments with the antisense compound or with saline were given from day 10 to day 17 post transplantation (total of 7 days) to four mice groups, containing approximately 17 animals each. PMO doses of 0.01, 0.03 and 0.1 mg/mouse/day were used. Bleeds were taken at days 16 (one day post treatment completion) and 21, and serum samples were evaluated.

Results are summarized in Table 9 and shown graphically in Figure 6. Viral loads are given as Mean Viral Load \pm SD (HCV-RNA copies/ml serum). Differences in percentages of HCV-positive animals between control and treated groups of mice are compared using the χ^2 analysis. Differences in viral loads between control and treated groups of mice (group pairs) are compared by the non-parametric Mann-Whitney U test.

Table 9. *In vivo* Antisense Dose-Response Efficacy Studies

Group	Viral Load	Percent HCV positive animals	P value
Saline	$1.91 \times 10^4 \pm 5.58 \times 10^3$	65	n=17
0.01 mg/day	$5.00 \times 10^3 \pm 1.39 \times 10^3$	29	0.03, n=17
0.03 mg/day	$2.79 \times 10^3 \pm 2.01 \times 10^2$	12	0.004, n=17
0.10 mg/day	$2.64 \times 10^3 \pm 1.39 \times 10^2$	6	0.002, n=18


From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

Table 10. Sequence Listing Table

SEQ ID NO.	Sequence, 5' to 3'
1	GTATCATAATGGGTGCTCAG
2	GTATCATAATGGGTGCTCAG
3	AATAATGAACATGTCTAGACAAGG
4	CTGTGATCATGGGCGCTCAG
5	TTGTTATCATGGGCGCTCAA
6	TTGGCATCATGGGTGCCAG
7	CAATGAGCACAACACTGACTGTTT
8	GACCCTATGAATACAACACTGACTGTTT
9	CAACAAAATGGGGGCTCAAG
10	GTAAATGAGAATTTGAGCTATGGCTCAAACGCTC
11	CGTGATGGCTAATTGCCGTC
12	GTGAATGATGATGGCGTCG
13	TGGAGGCCCATCAGTTTATTAAGG
14	GCCATGGAGGCCCATCAG
15	GACCGTGCACCATGAGCAC
16	CCTGAGCACCCATTATGATAC
17	CCTTGTCTAGACATGTTTATTATT
18	CTGAGCGCCCATGATCACAG
19	TTGAGCGCCCATGATAACAA
20	CTGGGCACCCATGATGCCAA
21	AAACAGTCAGTTGTGCTCATTG
22	AAACAGTCAGTTGTATTTCATAG
23	CTTGAGCTCCCATTTTGCTG
24	CTTGAGCCCCCATTTTTGTTG
25	CCTGTGCTCCCATCTTGATG
26	TGGGTGGGATCAACCCACAGGCTGTTTTAA
27	GAGCCATAGCTCAAATTCTC
28	TAGCTCAAATTCTCATTTAC
29	GAGCGTTTGAGCCATAGCTC
30	GACGGCAATTAGCCATCACG
31	CGACGCCATCATCATTAC
32	CAGAGTTTGAGACATTGTCTC
33	CCTTAATAAACTGATGGGCCTCC
34	CTGATGGGCCTCCATGGC
35	GTGCTCATGGTGCACGGTC
36	GACATATCTAATCATATAC

IT IS CLAIMED:

1. An antiviral compound directed against an RNA virus from the picornavirus, calicivirus, togavirus or flavivirus families, said virus having a single-stranded, positive
 5 sense genome of less than 12 kb and a first open reading frame that encodes a polyprotein containing multiple functional proteins, said compound comprising
 a morpholino oligomer having (a) a sequence of 12 to 40 morpholino subunits, supporting a targeting base sequence that is substantially complementary to a viral target sequence which spans the translation initiation region of said first open reading frame,
 10 and (b) a substantially uncharged backbone.
2. The compound of claim 1, wherein the subunits are connected by uncharged, phosphorus-containing intersubunit linkages, joining a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit.
- 15 3. The compound of claim 2, wherein said intersubunit linkages are phosphorodiamidate linkages.
4. The compound of claim 3, wherein said morpholino subunits are joined by
 20 phosphorodiamidate linkages, in accordance with the structure:



where $Y_1=O$, $Z=O$, P_j is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is alkyl, alkoxy, thioalkoxy, or alkyl amino.

5. The compound of claim 4, wherein $X=NR_2$, where each R is independently hydrogen or methyl.
6. The compound of claim 1, wherein said oligomer has a T_m , with respect to binding to said viral target sequence, of greater than about 50 °C, and said compound is actively taken up by mammalian cells.
7. The compound of claim 1, directed against a picornavirus, and having a targeting sequence having at least 90% homology to a sequence selected from the group consisting of:
- (i) SEQ ID NO. 16, for a polio virus of the Mahoney and Sabin strains,
 - (ii) SEQ ID NO. 17, for a hepatitis A virus,
 - (iii) SEQ ID NO. 18, for a rhinovirus 14,
 - (iv) SEQ ID NO. 19, for a rhinovirus 16,
 - (v) SEQ ID NO. 20, for a rhinovirus 1B,
 - (vi) SEQ ID NOs. 21 and 22, for an Aphthovirus, and
 - (vii) SEQ ID NOs 23, 24 and 25, for a coxsackie virus.
8. The compound of claim 7, directed against human rhinovirus 16, and having a targeting sequence represented by SEQ ID NO. 18 or 19.
9. The compound of claim 1, directed against a calicivirus, and having a targeting sequence having at least 90% homology to a sequence selected from the group consisting of:
- (i) SEQ ID NOs. 27, 28, and 29, for a serotype Pan-1 vesivirus,
 - (ii) SEQ ID NO. 30, for a porcine vesivirus,
 - (iii) SEQ ID NO. 31, for a Norwalk virus, and
 - (iv) SEQ ID NO. 32, for a feline vesivirus.
10. The compound of claim 9, directed against the serotype Pan-1 vesivirus, wherein the oligomer is a phosphorodiamidate-linked morpholino oligomer, having a targeting sequence selected from the group consisting of SEQ ID NOs. 27, 28, and 29.

11. The compound of claim 9, directed against the feline vesivirus, wherein the oligomer is a phosphorodiamidate-linked morpholino oligomer, having the targeting sequence SEQ ID NO. 32.
- 5 12. The compound of claim 1, directed against hepatitis E virus, and having a targeting sequence having at least 90% homology to a sequence selected from the group consisting of SEQ ID NOs. 33 and 34.
- 10 13. The compound of claim 12, wherein the oligomer is a phosphorodiamidate-linked morpholino oligomer having a sequence selected from the group consisting of SEQ ID NOs: 33 and 34.
14. The compound of claim 1, directed against a hepatitis C flavivirus, and having a targeting sequence having at least 90% homology to the sequence SEQ ID NO. 35.
- 15 15. The compound of claim 14, wherein the oligomer is a phosphorodiamidate-linked morpholino oligomer having the targeting sequence SEQ ID NO: 35.
16. The compound of claim 1, wherein said oligomer can be recovered, in a heteroduplex form consisting of the oligomer and a complementary portion of the viral genome of said RNA virus, from the serum or urine of a mammalian subject, several hours after being administered to said subject.
- 20 17. A method of inhibiting replication of an RNA virus from the picornavirus, calicivirus, togavirus or flavivirus families which has a single-stranded, positive sense genome of less than 12 kb, and a first open reading frame that encodes a polyprotein containing multiple functional proteins, comprising
- 25 exposing said virus to a morpholino oligomer having (a) a sequence of 12 to 40 morpholino subunits, supporting a targeting base sequence that is substantially
- 30 complementary to a viral target sequence which spans the translation initiation region of said first open reading frame, and (b) a substantially uncharged backbone.


18. The method of claim 17, wherein said oligomer is administered to a mammalian subject infected with said virus.

19. The method of claim 17, wherein said oligomer can be recovered from the serum or urine of said subject, several hours after said administering, in a heteroduplex form consisting of the oligomer and a complementary portion of the viral genome.

20. The method of claim 17, wherein the oligomer has uncharged, phosphorus-containing intersubunit linkages, joining a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit.

21. The method of claim 20, wherein said intersubunit linkages are phosphorodiamidate linkages.

22. The method of claim 21, wherein said morpholino subunits are joined by phosphorodiamidate linkages in accordance with the structure:



where $Y_1=O$, $Z=O$, P_j is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is alkyl, alkoxy, thioalkoxy, or alkyl amino.

23. The method of claim 22, wherein $X=NR_2$, where each R is independently hydrogen or methyl.

24. The method of claim 17, for inhibition of replication of a picornavirus, wherein said targeting sequence has at least 90% homology to a sequence selected from the group

consisting of:

- (i) SEQ ID NO. 16 for a polio virus of the Mahoney and Sabin strains,
- (ii) SEQ ID NO. 17, for a hepatitis A virus,
- (iii) SEQ ID NO. 18, for a rhinovirus 14,
- 5 (iv) SEQ ID NO. 19, for a rhinovirus 16,
- (v) SEQ ID NO. 20, for a rhinovirus 1B,
- (vi) SEQ ID NOs. 21 and 22, for an Aphthovirus,
- (vii) SEQ ID NOs 23, 24 and 25, for a coxsackie virus.

- 10 25. The method of claim 24, for inhibition of replication of human rhinovirus 16, wherein the targeting sequence is SEQ ID NO. 18 or 19, and the oligomer is a phosphorodiamidate-linked morpholino oligomer.

- 15 26. The method of claim 17, for inhibition of replication of a calicivirus, wherein said targeting sequence has at least 90% homology to a sequence selected from the group consisting of:

- (i) SEQ ID NOs. 27, 28 and 29, for a serotype Pan-1 vesivirus,
- (ii) SEQ ID NO. 30, for a porcine vesivirus,
- (iii) SEQ ID NO. 31, for a Norwalk virus, and
- 20 (iv) SEQ ID NO. 32, for a feline vesivirus.

- 25 27. The method of claim 26, for inhibition of replication of a serotype Pan-1 vesivirus, wherein the targeting sequence is selected from the group consisting of SEQ ID NOs. 27, 28, and 29, and the oligomer is a phosphorodiamidate-linked morpholino oligomer.

28. The method of claim 26, for inhibition of replication of a feline vesivirus, wherein the targeting sequence is SEQ ID NO. 32, and the oligomer is a phosphorodiamidate-linked morpholino oligomer.

- 30 29. The method of claim 17, for inhibition of replication of a hepatitis E virus, wherein the targeting sequence has at least 90% homology to a sequence selected from the group consisting of SEQ ID NOs. 33 and 34, and the oligomer is a phosphorodiamidate-linked

morpholino oligomer.

30. The method of claim 17, for inhibition of replication of a hepatitis C flavivirus, wherein the targeting sequence has at least 90% homology to SEQ ID NO: 35, and the
5 oligomer is a phosphorodiamidate-linked morpholino oligomer.

31. The method of claim 17, wherein said oligomer has a T_m , with respect to binding to said viral target sequence, of greater than about 50 °C, and is able to be actively taken up by mammalian cells.
10

32. A method of confirming the presence of an effective interaction between a picornavirus, calicivirus, togavirus or flavivirus infecting a mammalian subject, and an antisense oligomer targeted against the infecting virus, comprising
(a) administering said oligomer to the subject, wherein said oligomer has a sequence
15 of 12 to 40 morpholino subunits, supporting a targeting base sequence that is substantially complementary to a viral target sequence which spans the translation initiation region of the first open reading frame of the infecting virus,
(b) at a selected time after said administering, obtaining a sample of a body fluid from the subject; and
20 (c) assaying the sample for the presence of a nuclease-resistant heteroduplex comprising the antisense oligomer and a complementary portion of said viral target sequence.

33. The method of claim 32, wherein the oligomer has uncharged, phosphorus-containing intersubunit linkages, joining a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit.
25

34. The method of claim 33, wherein the linkages are phosphorodiamidate linkages.

30 35. The method of claim 32, for use in determining the effectiveness of treating a picornavirus, calicivirus, togavirus or flavivirus infection by administering said oligomer, wherein said administering, obtaining, and assaying is conducted at periodic

intervals throughout a treatment period.

36. A method of determining the family or genus of an infecting picornavirus, calicivirus, togavirus or flavivirus, the method comprising

- 5 (a) providing a plurality of antisense oligomers, each said oligomer having a base sequence that is substantially complementary to a viral target sequence of a plurality of known viruses selected from picornaviruses, caliciviruses, togaviruses or flaviviruses, wherein each said viral target sequence is (i) common to a virus family or genus, and (ii) not found in humans;
- 10 (b) administering at least one oligomer of the plurality to the subject,
- (c) at a selected time after said administering, obtaining a sample of a body fluid from the subject;
- (d) assaying the sample for the presence of a nuclease-resistant heteroduplex comprising the antisense oligomer and a complementary portion of the viral target
- 15 sequence, and
- (e) identifying the family or genus of the infecting virus, based on the presence or absence of a heteroduplex comprising an administered antisense oligomer and a complementary portion of said viral target base sequence.

- 20 37. The method of claim 36, for use in identifying a specific infecting picornavirus, calicivirus, togavirus or flavivirus, further comprising
 - providing a second plurality of antisense oligomers, each said oligomer having a base sequence that is substantially complementary to a viral target sequence of one of a plurality of known viruses from the family or genus identified in step (e), wherein each
 - 25 said viral target sequence is (i) specific to one of said known viruses, and (ii) not found in humans;
 - (b) administering at least one oligomer of the plurality to the subject,
 - (c) at a selected time after said administering, obtaining a sample of a body fluid from the subject;
 - 30 (d) assaying the sample for the presence of a nuclease-resistant heteroduplex comprising the antisense oligomer and a complementary portion of the viral target sequence, and

(e) identifying the infecting virus, based on the presence or absence of a heteroduplex comprising an administered antisense oligomer and a complementary portion of said viral target base sequence.

1/6




Fig. 1A




Fig. 1B




Fig. 1C




Fig. 1D




Fig. 1E

2/6




Fig. 2A




Fig. 2B




Fig. 2C
















Fig. 2D/E


3/6

**Fig. 3A****Fig. 3B****Fig. 3C****Fig. 3D**


4/6

**Fig. 4A****Fig. 4B****Fig. 4C****Fig. 4D****Fig. 4E****Fig. 4F****Fig. 4G****Fig. 4H**

5/6

**Fig. 5**

6/6

**Fig. 6**

SEQUENCE LISTING

<110> AVI BioPharma, Inc.

<120> Antisense Antiviral Agent and Method for
Treating ssRNA Viral Infection

<130> 504508046W00

<140> Not Yet Assigned

<141> Filed Herewith

<150> US 60/329,815

<151> 2001-10-16

<160> 36

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 20

<212> DNA

<213> Poliovirus Mahoney strain

<400> 1

gtatcataat gggtgctcag

20

<210> 2

<211> 20

<212> DNA

<213> Poliovirus Sabin strain

<400> 2

gtatcataat gggtgctcag

20

<210> 3

<211> 24

<212> DNA

<213> Hepatitis A virus

<400> 3

aataatgaac atgtctagac aagg

24

<210> 4

<211> 20

<212> DNA

<213> Rhinovirus 14

<400> 4

ctgtgatcat gggcgctcag

20

<210> 5

<211> 20

<212> DNA

<213> Rhinovirus 16

<400> 5

ttgttatcat gggcgctcaa

20

<210> 6

<211> 20

<212> DNA

<213> Rhinovirus 1B

<400> 6 ttggcatcat gggtgcccag	20
<210> 7	
<211> 22	
<212> DNA	
<213> Aphthovirus	
<400> 7 caatgagcac aactgactgt tt	22
<210> 8	
<211> 26	
<212> DNA	
<213> Aphthovirus	
<400> 8 gaccctatga atacaactga ctgttt	26
<210> 9	
<211> 20	
<212> DNA	
<213> Cocksackievirus	
<400> 9 caacaaaatg ggggctcaag	20
<210> 10	
<211> 34	
<212> DNA	
<213> Vesivirus (Pan-1)	
<400> 10 gtaaatgaga atttgagcta tggctcaaac gctc	34
<210> 11	
<211> 20	
<212> DNA	
<213> Porcine enteric calicivirus	
<400> 11 cgtgatggct aattgccgctc	20
<210> 12	
<211> 19	
<212> DNA	
<213> Norwalk virus	
<400> 12 gtgaatgatg atggcgctcg	19
<210> 13	
<211> 24	
<212> DNA	
<213> Hepatitis E virus	
<400> 13 tgaggccca tcagtttatt aagg	24
<210> 14	
<211> 18	
<212> DNA	
<213> Hepatitis C virus	

<400> 14
gccatggagg cccatcag 18

<210> 15
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic antisense oligomer

<400> 15
gaccgtgcac catgagcac 19

<210> 16
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic antisense oligomer

<400> 16
cctgagcacc cattatgata c 21

<210> 17
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic antisense oligomer

<400> 17
ccttgtctag acatgttcat tatt 24

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic antisense oligomer

<400> 18
ctgagcgccc atgatcacag 20

<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic antisense oligomer

<400> 19
ttgagcgccc atgataacaa 20

<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic antisense oligomer

<400> 20
 ctgggcaccc atgatgcca 20

 <210> 21
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> synthetic antisense oligomer

 <400> 21
 aaacagtcag ttgtgctcat tg 22

 <210> 22
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> synthetic antisense oligomer

 <400> 22
 aaacagtcag ttgtattcat ag 22

 <210> 23
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> synthetic antisense oligomer

 <400> 23
 cttgagctcc catttttgctg 20

 <210> 24
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> synthetic antisense oligomer

 <400> 24
 cttgagcccc catttttggt g 21

 <210> 25
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> synthetic antisense oligomer

 <400> 25
 cctgtgctcc catcttgatg 20

 <210> 26
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> synthetic antisense oligomer

<400> 26
tgggtgggat caaccacag gctgttttaa 30

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic antisense oligomer

<400> 27
gagccatagc tcaaattctc 20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic antisense oligomer

<400> 28
tagctcaaat tctcatttac 20

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic antisense oligomer

<400> 29
gagcgtttga gccatagctc 20

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic antisense oligomer

<400> 30
gacggcaatt agccatcacg 20

<210> 31

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic antisense oligomer

<400> 31
cgacgccatc atcattcac 19

<210> 32

<211> 21

<212> DNA

<213> Artificial Sequence

<220>
<223> synthetic antisense oligomer

<400> 32
cagagtttga gacattgtct c 21

<210> 33
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic antisense oligomer

<400> 33
ccttaataaaa ctgatgggcc tcc 23

<210> 34
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic antisense oligomer

<400> 34
ctgatgggcc tccatggc 18

<210> 35
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic antisense oligomer

<400> 35
gtgctcatgg tgcacggtc 19

<210> 36
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> scrambled control sequence

<400> 36
gacatatcta atcatatac 19

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 April 2003 (24.04.2003)

PCT

(10) International Publication Number
WO 2003/033657 A3

(51) International Patent Classification⁷: **C07H 21/04**

(21) International Application Number:
PCT/US2002/032868

(22) International Filing Date: 16 October 2002 (16.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/329,815 16 October 2001 (16.10.2001) US

(71) Applicant: AVI BIOPHARMA, INC. [US/US]; Suite
200, 4575 S.W. Research Way, Corvallis, OR 97333 (US).

(72) Inventors: STEIN, David, A.; 1610 N.W. 23rd Street,
Corvallis, OR 97330 (US). SKILLING, Douglas, E.; 2634
N.W. Acey Place, Corvallis, OR 97330 (US). IVERSEN,
Patrick, L.; 5902 N.W. Fair Oaks Place, Corvallis, OR
97330 (US). SMITH, Alvin, W.; 26833 Sulphur Springs
Road, Corvallis, OR 97330 (US).

(74) Agents: GORTHEY, LeeAnn et al.; Perkins Coie LLP,
P.O. Box 2168, Menlo Park, CA 94026 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
13 May 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2003/033657 A3

(54) Title: ANTISENSE ANTIVIRAL AGENT AND METHOD FOR TREATING SSRNA VIRAL INFECTION

(57) Abstract: This invention provides antisense antiviral compounds and methods of their use in inhibition of growth of viruses of the picornavirus, calicivirus, togavirus and flavivirus families, as in treatment of a viral infection. The antisense antiviral compounds are substantially uncharged oligomers having a targeting base sequence that is substantially complementary to a viral target sequence which spans the AUG start site of the first open reading frame of the viral genome.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/32868

A. CLASSIFICATION OF SUBJECT MATTER														
IPC(7) : C07H 2104 US CL : 536/24.3														
According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED														
Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/216.1, 218.1; 435/6; 514/43; 536/23.72, 24.3														
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched														
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
Y --- A	SUMMERTON et al. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Development, June 1997 Vol. 7, No. 3, pages 187-195.	1-7, 14-24, 30-37 ----- 8-13, 25, 26, 28												
Y --- A	PARTRIDGE et al. A simple method for delivering morpholino antisense oligos into the cytoplasm of cells. Antisense Nucleic Acid Drug Development, 1996, Vol. 6, No. 3, pages 169-175.	1-7, 14-24, 30-37 ----- 8-13, 25, 26, 28												
Y	ZHANG et al. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrobial Agents Chemotherapy. February 1999, Vol. 43, No. 2, pages 347-353.	1-6, 14-23, 30-37												
Y	WANG et al. Specific inhibition of coxsackievirus B3 translation and replication by phosphorothioate antisense oligodeoxynucleotides. Antimicrobial Agents Chemotherapy, April 2001, Vol. 45, No. 4, pages 1043-1052.	1-6, 16-23, 31-37												
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"> <tr> <td colspan="2">* Special categories of cited documents:</td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"B" earlier application or patent published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:		"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:														
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family													
"P" document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 28 July 2003 (28.07.2003)		Date of mailing of the international search report 25 NOV 2003												
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230		Authorized officer <i>Valerie Bell-Harris for</i> Strike Winkler Telephone No. 703-308-0196												

INTERNATIONAL SEARCH REPORT

PCT/US02/32868

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	STEIN et al. Inhibition of vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Development, October 2001, Vol. 11, No. 5, pages 317-325.	1-6, 9-11, 16-23, 26-28, 31-37
X, P	SMITH et al. Antisense treatment of caliciviridae: an emerging disease agent of animals and humans. Current Opinion Molecular Therapeutics, April 2002, Vol. 4, No. 2, pages 177-184.	1-6, 9-11, 16-23, 26-28, 31-37
Y	US 5,702,891 (KOLBERG et al.) 30 December 1997 (30.12.1997), see SEQ ID NO:16.	1, 7, 17, 24
Y	US 5,576,302 (COOK et al) 19 November 1996 (19.11.1996), see SEQ ID NO: 4.	1, 14, 15, 17, 30
Y	US 6,174,868 (ANDERSON et al.) 16 January 2001 (16.01.1996), see SEQ ID NO: 6.	1, 14, 15, 17, 30

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/32868

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 1-37, as they read on SEQ ID NO: 16, 17, 18, 23, 27, 30, 31, 32, 33 and 35

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☒

- The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US02/32868

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group 1, claim(s) 1-7, 16-24 and 31, drawn to an antiviral compound directed to a RNA sequence comprising the SEQ ID NO: 16 belonging to the family Picornaviridae and the genus Enterovirus (poliovirus) and a method of inhibiting the virus.

Group 2, claim(s) 1, 7, 17 and 24, drawn to an antiviral compound directed to a RNA sequence comprising the SEQ ID NO: 17 belonging to the family Picornaviridae and the genus Hepatovirus.

Group 3, claim(s) 1, 7, 8, 17, 24 and 25, drawn to an antiviral compound directed to a RNA sequence comprising the SEQ ID NO: 18 belonging to the family Picornaviridae and the genus Rhinovirus.

Group 4, claim(s) 1, 7, 8, 17, 24 and 25, drawn to an antiviral compound directed to a RNA sequence comprising the SEQ ID NO: 19 belonging to the family Picornaviridae and the genus Rhinovirus.

Group 5, claim(s) 1, 7, 17 and 24, drawn to an antiviral compound directed to a specific RNA sequence comprising the SEQ ID NO: 20 belonging to the family Picornaviridae and the genus Rhinovirus.

Group 6, claim(s) 1, 7, 17 and 24, drawn to an antiviral compound directed to a RNA sequence comprising the SEQ ID NO: 21 belonging to the family Picornaviridae and the genus Aphthovirus.

Group 7, claim(s) 1, 7, 17 and 24, drawn to an antiviral compound directed to a RNA sequence comprising the SEQ ID NO: 22 belonging to the family Picornaviridae and the genus Aphthovirus.

Group 8, claim(s) 1, 7, 17 and 24, drawn to an antiviral compound directed to a RNA sequence comprising the SEQ ID NO: 23 belonging to the family Picornaviridae and the genus Enterovirus (coxsackievirus).

Group 9, claim(s) 1, 7, 17 and 24, drawn to an antiviral compound directed to a RNA sequence comprising the SEQ ID NO: 24 belonging to the family Picornaviridae and the genus Enterovirus (coxsackievirus).

Group 10, claim(s) 1, 7, 17 and 24, drawn to an antiviral compound directed to a RNA sequence comprising the SEQ ID NO: 25 belonging to the family Picornaviridae and the genus Enterovirus (coxsackievirus).

Group 11, claim(s) 1, 9, 10, 17, 26 and 27, drawn to an antiviral compound directed to a specific RNA sequence comprising the SEQ ID NO: 27 belonging to the family Caliciviridae and the genus Vesivirus.

Group 12, claim(s) 1, 9, 10, 17, 26 and 27, drawn to an antiviral compound directed to a specific RNA sequence comprising the SEQ ID NO: 28 belonging to the family Caliciviridae and the genus Vesivirus.

Group 13, claim(s) 1, 9, 10, 17, 26 and 27, drawn to an antiviral compound directed to a specific RNA sequence comprising the SEQ ID NO: 29 belonging to the family Caliciviridae and the genus Vesivirus.

Group 14, claim(s) 1, 9, 17 and 26, drawn to an antiviral compound directed to a specific RNA sequence comprising the SEQ ID NO: 30 belonging to the family Caliciviridae and the genus Vesivirus.

Group 15, claim(s) 1, 9, 17 and 26, drawn to an antiviral compound directed to a specific RNA sequence comprising the SEQ ID NO: 31 belonging to the family Caliciviridae and the genus Calicivirus (Norwalk virus).

Group 16, claim(s) 1, 9, 11, 17, 26 and 28, drawn to an antiviral compound directed to a specific RNA sequence comprising the SEQ ID NO: 32 belonging to the family Caliciviridae and the genus Vesivirus.

INTERNATIONAL SEARCH REPORT

PCT/US02/32868

Group 18, claim(s) 1, 12, 13, 17 and 29, drawn to an antiviral compound directed to a specific RNA sequence comprising the SEQ ID NO: 33 belonging to hepatitis E virus.

Group 19, claim(s) 1, 12, 13, 17 and 29, drawn to an antiviral compound directed to a specific RNA sequence comprising the SEQ ID NO: 34 belonging to hepatitis E virus.

Group 20, claim(s) 1, 14, 15, 17 and 30, drawn to an antiviral compound directed to a specific RNA sequence comprising the SEQ ID NO: 35 belonging to the family Flaviviridae (hepatitis C virus).

Group 21, claim(s) 32-37, drawn to a method treating a subject and measuring the interaction of the compound with viral RNA by measuring the nuclease resistance of the heteroduplex.

The inventions listed as Groups 1-21 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

According to PCT Rule 13.2, unity of invention only exists when the shared same or corresponding technical feature is a contribution over the prior art. The inventions listed as Groups 1-21 do not relate to a single general inventive concept because they lack the same or corresponding technical feature. The technical feature of group 1 (specifically claims 1-6) the antiviral compound directed against an RNA virus comprising a morpholino oligomer spanning the translation initiation region of the first open reading frame which is shown by Stein et al. (Antisense Nucleic Acid Drug Development, October 2001) to lack novelty or inventive step and does not make a contribution over the prior art.

The special technical feature of group 1 is not required for the methods of any of groups 2-20 and vice versa, therefore, unity of invention is lacking between the groups.

The special technical feature of group 21 is considered to be the treatment of the subject and the analysis of the heteroduplex formation between the viral RNA and the morpholino compound.

Accordingly, Groups 1-21 are not so linked as to form a single general inventive concept and restriction is proper.

Continuation of B. FIELDS SEARCHED Item 3:

WEST, DERWENT, STN-BIOSIS, MEDLINE, EMBASE

morpholino oligomer, phosphorodiamidate, PMO, antisense, RNA virus, translation initiation.